AP866A

AP866A - Benzimidazole compounds.

Info

Publication number: AP866A
Application number: APAP/P/1998/001183A
Authority: AP
Inventors: Roger John Griffin; Alan Hilary Calvert; David Richard Newell; Nicola Jane Curtin; Bernard Thomas Golding
Original assignee: Newcastle Univ Ventures Limited
Priority date: 1995-08-02
Filing date: 1996-07-30
Publication date: 2000-08-17
Also published as: HUP9901092A3; DE69624115D1; KR100447539B1; NO980414L; CA2225465A1; SK13598A3; EA199800184A1; OA10661A; BR9610051A; NO980414D0; PL324869A1; CZ30398A3; CN1159007C; MX9800927A; WO1997004771A1; US6310082B1; IL123147A0; DE69624115T2; AU714873B2; ATE225173T1

Abstract

A range is disclosed of benzimidazole-4-carboxamide compounds (I) which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DMA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. In formula (I), R and R' may each be selected independently from hydrogen, alkyl, hydroxyalkyl (e.g. CH2CH2OH), acyl (e.g. acetyl or benzoyl) or an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group. R is generally a substituted phenyl group in the most preferred compounds. The compounds may also be used in the form of pharmaceutically acceptable salts or pro-drugs.

Description

BENZIMIDAZOLE COMPOUNDS

The present invention relates to certain benzimidazole compounds that are of interest as being at least potentially useful chemotherapeutic agents by virtue of an ability to inhibit the activity of the enzyme poly ADP-ribosyltransferase (EC 2.4.2.30), also known as poly(ADP-ribose) polymerase, commonly referred to as ADPRT or PARP. In general, the latter abbreviation, PARP, will be used throughout the present specification.

BACKGROUND

At least in higher organisms, the enzyme poly ADP15 ribosyltransferase is known to catalyse a transfer of the ADP-ribose moiety from the oxidized form, NAD⁺, of nicotinamide adenine dinucleotide to nuclear acceptor proteins so as to form homo ADP-ribose polymers, and this process has been implicated in a number of cellular events such as, for example, repair of DNA damage, development of cellular differentiation, transformation of cells by oncogenes, and gene expression. A common feature in a number of these processes is the formation and repair of DNA strand breaks and the stage which involves the PARP enzyme appears to be that of DNA ligase II-mediated strand rejoining. In the majority of cases a role for poly ADP-ribosylation has been implicated by the use of inhibitors of the PARP enzyme, and this has led to suggestions that such inhibitors, by interfering with the intracellular DNA repair mechanism, may have a useful chemotherapeutic role insofar as they should be able to modify treatment resistance characteristics and potentiate or enhance the effectiveness of cytotoxic drugs in chemotherapy or of radiation in radiotherapy where a primary effect of the treatment is that of causing DNA damage in target cells, as for example in many forms of antitumour therapy.

AP/P/ 9 8/01183

In this connection, several classes of PARP

APO Ο Ο 8 6 6 inhibitors are already known, including benzamide and various nicotinamide and benzamide analogues, especially

3-substituted benzamides with small substituent groups such as 3-amino, 3-hydroxy and 3-methoxy. PARP inhibitory activity of certain N-substituted benzamides has also been reported in EP-A-03 05 008 wherein it has also been proposed to use these compounds in medicine for increasing the cytotoxicity of radiation or of chemotherapeutic drugs .

of benzamide compounds as various studies on such to exhibit PARP inhibitory they can potentiate the

Regarding this use chemotherapeutic agents, compounds that are known activity have confirmed that cyt oxi city of a range of antitumour agents in vitro, for example, bleomycin and methylating drugs. More limited data has further indicated that such benzamide compounds can also potentiate the activity of cytotoxic drugs in vivo, although the dose requirements have appeared to be rather high (e.g. in the region of 0.5g kg^-1 per dose for 3-aminobenzamide) and there may be associated problems in preparing satisfactory pharmaceutical formulations and in avoiding toxicity limitations. Furthermore, a number of the known benzamide compounds have also been shown clearly to have potential as radiosensitizers, increasing for example ionising radiation-induced tumour cell kill both in vitro and in vivo, and it is believed that in many cases this effect is related to these compounds acting as PARP inhibitors and interfering with DNA repair.

£81 10/86 /d/dV

However, notwithstanding the existing data from in vitro and in vivo studies suggesting that PARP inhibitors have considerable potential as useful chemotherapeutic agents which merit further clinical evaluation, for instance in connection with cancer therapy, currently ava Ahi a known PARP inhibitors are not considered as yet to be entirely suitable to represent candidate drugs and there remains a need to find and develop a greater range

APO Ο Ο 8 6 6 of compounds having potentially useful PARP inhihjtory properties .

DISCLOSURE OF THE INVENTION

The present invention identifies a new range or ranges of compounds of interest as PARP inhibitors that can be useful in medicine, especially when administered in conjunction with at least certain cytotoxic drugs or with radiotherapy for increasing the cytotoxic effectiveness thereof. In general, the compounds to which this invention relates comprise certain benzimidazole derivatives, more particularly benzimidazole-4-carboxamide compounds, as hereinbelow defined. By virtue of their structure it would appear that many such compounds are particularly well adapted to compete with the ' natural substrate NAD⁺ for the PARP enzyme .

More specifically, from one aspect, the invention resides in the use of a compound as herein defined for the manufacture of a medical or veterinary preparation for use in therapy for inhibiting activity of the enzyme poly(ADP-ribose)polymerase or PARP (also known as ADPribosyl transferase or ADPRT), such enzyme inhibition constituting an element of a therapeutic treatment, wherein said compound provides the active PARP enzyme inhibiting agent and comprises a benzimidazole-430 carboxamide having the general structural formula I

AP/P/ 9 8/01 183

AP C Ο Ο 8 6 6 or a pharmaceutically acceptable salt and/or pro-drug form thereof, characterised in that in structural formula I 5

R is selected from hydrogen, alkyl, hydroxyalkyl (e.g. CH2CH2OH), acyl (e.g. acetyl or benzoyl) and an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group, and

R' is selected from hydrogen, alkyl, hydroxyalkyl (e.g. CH2CH2OH) , acyl (e.g. acetyl or benzoyl) and an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group.

The invention also provides for use in therapy, as active pharmaceutical substances, especially but not exclusively as PARP inhibitors, benzimidazole compounds having the general structural formula I

ΑΡ/Γ/ 9 8/01183 (or a pharmaceutically acceptable salt and/or pro-drug form thereof), with substituents as defined above except that if R is acyl it is acetyl or benzoyl, and R does not represent 4'-methanesulphonyloxy-2'-methoxyphenyl or 4'35 methanesulphonylamino-2'-methoxyphenyl· and does not represent a phenyl group having a substituent which is an alkylsulphenyl, alkylsulphinyl, alkanesulphonyl or alkylsulphoximino group, an alkylsulphoximino group substituted at the nitrogen atom by an alkanoyl,

AP C ΰ ό 8 6 6

4a alkylsulphonyl or hydroxycarbonyl-alkylenecarbonyl group, an ethoxy or n-propoxy group each of which is substituted in the terminal position by an alkylsulphenyl, alkylsulphinyl, alkanesulphonyl or alkylsulphoximino group, an alkoxycarbonylamino or an N-alkylaminocarbonylamino group and R' is not an optionally substituted aralkyl group and does not include a biphenyl or substituted biphenyl group.

The invention as claimed further provides novel benzimidazole compounds having the general structural formula I (or a pharmaceutically acceptable salt and/or pro-drug form thereof) , with substituents as defined immediately above except for the further proviso that R does not represent an unsubstituted aryl group such as phenyl, an optionally substituted aralkyl group, or an alkyl group .

ΑΡ/Γ/ 9 8/01183

AP Ο Ο Ο 8 6 6

Alkyl groups when present as such or as a moiety in other groups will generally be composed of 1-8 carbon atoms, preferably 1-6 carbon atoms, and more usually 1-4 carbon atoms. In particular, when R and/or R' is an alkyl group this will generally be alkyl, such as for example methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl or cyclohexyl. When R and/or R' is or includes a phenyl group this may be substituted, especially in the 4 (para) position but alternatively or additionally in the 2-position and/or 3-position for instance, by various substituents including hydroxy, alkoxy (methoxy or ethoxy * for example), cyano, carboxy, amide, tetrazole, amino or substituted halogen.

amino, CW3 (e.g. CF3) or W where W is

In cases where R¹compounds of structural which R is phenyl is hydrogen or alkyl preferred formula I include compounds in or benzyl having at least one £βννθ/86 ld!dN substituent in the benzene ring which is selected from hydroxy, alkoxy, NO2, N3, NRgRg (R5 and Rg each being independently hydrogen, alkyl or alkoxy), NHCOR3 (R3 being alkyl or aryl) , CO2R4 (R4 being H or alkyl) , an amide (e.g. CONH2), tetrazole, alkyl, hydroxyalkyl, CW3 or W (W being halogen), and CN.

More particularly, where R represents a substituted phenyl group having the structural formula II

Rl, R₂ and Rg may be each selected independently from H,

APOOO866 hydroxy, alkoxy, NO₂, N₃, NRgRg (R₅ and Rg each being independently hydrogen, alkyl or alkoxy), nhcor₃ (r₃being alkyl or aryl) , CO₂R₄ (R4 being H or alkyl) , an amide (e.g. CONH₂) , tetrazole, alkyl, hydroxyalkyl, cw₃ or W (W being halogen), and CN.

The invention also includes a process for preparing a compound of structural formula I as specified above wherein R represents an optionally substituted phenyl group having the structural formula II, said process comprising the .steps of reacting an alkyl 2,3diaminobenzoate with an aryl acid chloride, treating the product with acetic acid at an elevated temperature to bring about benzimidazole ring formation, and reacting with liquid ammonia to form the amide derivative.

Where R' represents a substituted phenyl group having the structural formula III

AP/F/ 9 8/01 1 a 3

R7, Rg and R]_q may be each selected independently from H, hydroxy, alkoxy, NO₂, N₃, NRgRg (Rg and Rg each being independently hydrogen, alkyl or alkoxy), NHCOR₃ (R₃ being alkyl or aryl) , CO₂R4 (R₄ being H or alkyl) , an amide (e.g. CONH₂), tetrazole, alkyl, hydroxyalkyl, CW₃ or W (W being halogen), and CN.

Compounds of structural formula I as hereinabove defined which have an aromatic ring that includes a CN substituent may often also be particularly useful as intermediates in making other compounds in accordance

AP Ο Ο Ο 86 6 with the invention since a cyano substituent can generally be converted, using standard methodology, into a variety of other functional groups, including amine, carboxyl, amide and tetrazole.

Within the ranges of benzimidazole compounds disclosed herein, preferred members which are of particular interest include (a) 2-methylbenzimidazole-4-carboxamide,· (b) benzimidazole-4-carboxamide;

(c) 2-phenylbenzimidazole-4-carboxamide;

(d) 2-(4'-methoxyphenyl) benzimidazole-4-carboxamide,· (e) 2- (4 ' -trifluoromethyIphenyl)benzimidazole-4carboxamide;

(f) 2-(4'-hydroxyphenyl)benzimidazole-4-carboxamide,· (g) 2-trifluoromethylbenzimidazole-4-carboxamide;

(h) 2-(4'-methoxyphenyl)-N-methylbenzimidazole-4carboxamide,· (i) 2- (4 '-nitrophenyl)benzimidazole-4-carboxamide;

(j) 2- (4'-cyanophenyl)benzimidazole-4-carboxamide;

(k) 2- (3¹ -trifluoromethylphenyl)benzimidazole-4carboxamide;

(l) 2-(3'-methoxyphenyl)benzimidazole-4-carboxamide;

(m) 2- (4 ¹ -methoxyphenyl)-l-N-benzoylbenzimidazole-4carboxamide, (n) 2-(4'-aminophenyl)benzimidazole-4-carboxamide (o) 2- (2 ¹ -trifluoromethylphenyl)benzimidazole-4carboxamide, (p) N-carboxybenzyl-2-(4'-methoxyphenyl)benzimidazole-4-carboxamide .

AP/P/ 9 8/01183

In the above-mentioned compounds of this invention wherein there is an electron-rich aromatic ring, it is believed that in at least some cases the carboxamide group may be constrained in a fixed conformation, particularly favourable for presenting the compound as an inhibitor of NAD⁺ binding to the PARP enzyme, by an intramolecular hydrogen bond between an imidazole ring

APO Ο Ο 8 6 6 nitrogen atom and one of the hydrogen atoms of the carboxamide group.

As already indicated, the invention also embraces or extends to methods of preparing compounds as hereinbefore defined (including intermediates in some cases) and to the therapeutic use of such compounds in treating mammals. This includes their use for making medical or veterinary preparations or pharmaceutical formulations containing an effective PARP inhibitory amount of the active compound for administration to a patient in conjunction with a cytotoxic drug or · radiotherapy in · order to increase the cytotoxic effectiveness of the latter. Such preparations or formulations may be made up in accordance with any of the methods well known in the art of pharmacy for administration in any suitable manner, for example orally, parenterally (including subcutaneously, intramuscularly or intravenously), or topically, the mode of administration, type of preparations or formulation and the dosage being generally determined by the details of the associated cytotoxic drug chemotherapy or radiotherapy that is to be enhanced.

²⁵ In making up such pharmaceutical formulations in the form of sterile liquid preparations for parental use for instance, a predetermined therapeutically effective non-toxic amount of the particular compound concerned may be dissolved in phosphate buffered saline and the ²⁰ preparations may be presented in unit dosage form and contained in sealed ampoules ready for use. In general, at least in aqueous solution, concentrations not greater than 200mg/ml will be preferred, but the amount and dosage routine required for optimum effectiveness will of ²⁵ course vary and is ultimately at the discretion of the medical or veterinary practitioner treating the mammal concerned in each particular case. Where the compound is to be used in conjunction with a cytotoxic drug, the latter in some cases may be administered simultaneously

AP/P/ 9 8/01183

ΑΡΟ Ο Ο 8 6 6 and may be conveniently incorporated in the same pharmaceutical formulation or composition.

As indicated, the compounds according to this invention have at least potential as PARP inhibitors, and in vitro tests hereinafter described have demonstrated positive pharmacological activity which it is believed reflects the activity to be found in vivo in the course of therapeutic clinical use.

It will be understood that where reference is made in this specification to compounds of formula I such reference should be construed as extending also to their pharmaceutically acceptable salts and to other pharmaceutically acceptable * bioprecursors (pro-drug forms) where relevant. The term pro-drug is used in the present specification to denote modified forms or derivatives of a pharmacologically active compound which biodegrade in vivo and become converted into said active compound after administration, especially oral or intravenous administration, in the course of therapeutic treatment of a mammal. Such pro-drugs are commonly chosen because of an enhanced solubility in aqueous media which helps to overcome formulation problems, and also in some cases to give a relatively slow or controlled release of the active agent.

A satisfactory pro-drug must generally be a watersoluble derivative which is non-toxic and reasonably stable in solution at physiological pH but which will biodegrade or convert, e.g. by enzymatic degradation or by an enviromental pH change, to the active compound at the location required following administration in the course of therapy. For the benzimidazole compounds of the present invention, pro-drug forms may conveniently be provided by carbamate or amino acid derivatives, e.g. glycine or other amino-acid carbamate derivatives, or by phosphate derivatives. Phosphate derivatives may be susceptible to enzymic dephosphorylation in vivo and are

AP/P/ 9 8/01183

AP C ύ ύ 8 6 6 presently preferred, especially water-soluble ammonium or alkali metal phosphate salts. These may often be conveniently prepared from compounds of structural formula I having at least one hydroxyl group snhat-j t-uent,

e.g. in an aromatic ring component of R, by reacting with a dibenzyl phosphonate, preferably in the presence of a tertiary base such as N, N-diisopropylethylamine.

In cases where R is phenyl (or benzyl) and where it 10 is necessary to have a substituent other than hydroxyl, e.g. NO2, COgH, CN etc. at the 4' position in order to give satisfactory PARP inhibitory activity, a hydroxyl substituent amenable to phosphorylation or other pro-drug modification may be provided at another aromatic ring position, e.g. at the 3' position.

*

In all the water-soluble pro-drug forms presently envisaged the phosphate, carbamate or other watersolubilizing pro-drug moiety will be a component of R or

R' in structural formula I.

It should also be understood that where any of the compounds referred to can exist in more than one enantiomeric form, all such forms, mixtures thereof, and their preparation and uses are within the scope of the invention.

AP/P/ 9 8/01183

AP C Ο Ο 8 6 6

DESCRIPTION OF EXAMPLES OF PREFERRED EMBODIMENTS

The following examples and descriptions of stages in synthetic routes of preparation of various preferred compounds of interest serve to further illustrate the present invention, but should not he construed in any way as a limitation thereof.

In the first example (EXAMPLE 1), the preparation is described of various intermediate compounds required for the preparation of benzimidazole compounds in accordance with the present invention which are described in EXAMPLES 2 to 6.

*

EXAMPLE 1

Preparation of Intermediate Compounds (a) 3-Nitroohthalamic acid

3-Nitrophthalic anhydride (lO.Og, 50 mmol) 'was added in portions over 20 minutes to concentrated aqueous ammonia solution (15ml) , and the mixture was stirred at 30°C for a further 3 0 minutes. The crystalline mass of ammonium phthalamate, deposited upon cooling the pale yellow solution, was collected and redissolved in a minimum amount of warm water. Concentrated hydrochloric acid (4.5ml) was added dropwise, with stirring, and the resulting paste was washed with water, and dried in vacuo

0 to give 3-nitrophthalamic acid as a fine white powder. (9.Olg, 83%), m.p. 217°C Found: C, 45.76; H, 2.79; N, 13.21.

CgHgN2O5 requires C, 45.71; H, 2.86; N, 13.33%; η^/ση'¹3466.52, 3321.84, 1668.64, 1604.98, and 1525.89; δ_Η (dg35 DMSO, 200 MHz) 7.75 (1H, br s, CONH), 7.8 (1H, t, Ar-5H), 8.16 (1H, brs, CONH), 8.2 (1H, d, Ar-6H) , 8.3 (1H, d, Ar4H); 5_C (dg-DMSO) 127.32, 130.06, 132.28, 133.49, 134.78, 147.71, 166.25, and 166.60; m/z (El) 192 (M+-1) , 177,

149, 103, 75.

AP/P/ 9 8/01183

APC Ο Ο 8 6 6 (b) 2-Amino-3-nitrobenzoic acid (3-nitroanthranilic acid)

To a stirred solution of potassium hydroxide (24. lg) in water (110ml) at 0°C was added bromine (2.46ml), followed by 3-nitrophthalamic acid lOg,

47.62mmol). The reaction mixture was stirred for 3 hours at 60°C, cooled to room temperature, and stirred for a further 12 hours. The orange precipitate was collected, redissolved in a minimum amount of water, and acidified by the dropwise addition of concentrated hydrochloric acid. Recrystallisation of the resulting yellow solid from hot water afforded 3-nitroanthranilic acid as yellow microcrystals (6.42g, 74%), m.p. 208-209°C

Found: C, 45 /83; H, 3.07; N, 15.21.

C7H5N2O4 requires C, 46.15; H, 3.29; N, 15.38%;

3476.17, 3344.99, 3094.21 and 1687.93; δ_Η (dg-DMSO,

200MHz) 6.76-6.84 (1H, t, Ar-5H), 8.29-8.41 (2H, dd, Ar4/6H), 8.60 (2H, s, Ar-NH₂), 13.4-14.0 (1H, br s, Ar20 CO₂H) ; 0_C (dg-DMSO) 113.19, 131.97, 140.02 (Ar-4/5/6CH),

115.02 (Ar-C-NH₂), 132.77 (Ar-C-CO₂H), 147.09 (Ar-C-NO₂),

168.95 (Ar-CO₂H); m/z (El) 182'(M⁺), 164.

(c) Methyl 2-amino-3-nitrobenzoate

Hydrogen chloride gas was bubbled through a solution of 2-amino-3-nitrobenzoic acid (0.5g, 2.75 mmol) in methanol (40ml) for 15 minutes at 0°C. The reaction mixture was heated under reflux for 5 hours, and allowed

0 to cool to room temperature over a further 12 hours, whereupon methyl 2-amino-3-nitrobenzoate was deposited as a yellow solid (417tng, 77%), m.p. 95-96°C

Found: C, 49.09: H, 3.78; N, 14.03.

CgHgN₂O₄ requires C, 48.98; H, 4.08; N, 14.29%; v’_max/_cm_₁

3452.5, 3316.9, 1702, and 1253.7; δ_Η )dg-DMSO, 200 MHz)

3.95 (3H, s, OCHH3), 6.79-6.87 (1H, t, Ar-5H), 8.28-8.33 (1H, dd, ΑΓ-4Η) , 8.41-8.46 (1H, dd, Ar-6H), 8.45-8.46 (2H, br s, Ar-NH-?);· m/z (El) 196 (M+) , 164, 118, 90, 63.

AP/P/ 9 8/01183

AP C ϋ Ο 8 6 6 (d) 2,3-Diaminobenzoic Acid

Palladium on carbon catalyst (10% Pd, ~200mg) was added cautiously, as a slurry in methanol (10ml) , to a solution of 3-nitroanthranilic acid (2.44g, 13 mmol) in methanol (120ml), and the mixture was stirred under a hydrogen atmosphere for 2 hours until the absorption of gas ceased. The catalyst was removed by filtration through Celite, and the filtrate was evaporated to dryness under reduced pressure to afford the crude product. Purification by column chromatography on silica gel, with dichloromethane:methanol (4:1) as eluent, gave 2,3-diaminobenzoic acid as a red solid (1.34g, 66%).

Vmax/cm¹ 3433.73, 2882.02, 2602.30 and 1658.99; δ_Η (dgDMSO, 200 MHZ) 5.8-7.4 (4H, br S, 2 x NH₂) , 6.45* (IH, t, Ar-5H) , 6.75 (IH, d, Ar-4H) , 7.20 (IH, d, Ar-6H); 5_C (dgDMSO) 110.31, 115.45, 118.33, 120.55, 135.03, 140.36,

170.68; m/z (El) 152 (M⁺), 134, 106, 79.

(e) Methyl 2,3-diaminobenzoate

A solution of 2,3-diaminobenzoic acid (0.2g, 1.32 mmol) in methanol (40ml) was saturated with hydrogen chloride as described above, and the mixture was subsequently heated under reflux for 2 hours. The solid residue obtained on evaporation of the solvent was dissolved in water, and the solution was adjusted to pH 7.0 with sodium hydrogen carbonate. After extraction with ethyl acetate (2 x 30ml), the combined organic layers were dried (MgSO^ , and the solvent was removed to give methyl 2,3-diaminobenzoate as a brown oil which solidified on trituration with petrol (40/60) (121.6mg,

56%), m.p. 62-63°C

Found: C, 58.35; H, 5.80; N, 16.69.

^c8^H10^N2°2 requires C, 57.83,- H, 6.02; N, 16.87%; δ_Η (dg-DMSO), 200MHz) 3.87 (3H, s, OCH₃). 4.90 (2H, br s, Ar-2-NH₂), 6.32 (2H, br s, Ar-3-NH₂), 6.46-6.54 (IH, t,

Ar-5H), 6.80-6.84 (IH, dd, Ar-4H), 7.18-7.23 (IH, dd, ArAP/P/ 9 8/01 183

AP c ο Ο 8 6 6

6H) ; m/z (El) 166 (M+), 134, 106, 79.

Methyl 2,3-diaminobenzoate was also prepared by reduction of methyl 2-amino-3-nitrobenzoate as follows: a solution of methyl 2-amino-3-nitrobenzoate (284mg, 1.45 mmol) in methanol (40ml), containing palladium on carbon catalyst (10% Pd, ~50mg), was stirred under hydrogen for 24 hours. The solution was filtered through Celite to remove the catalyst, and the solvent was evaporated in vacuo to afford the methyl ester as a brown solid. (180mg, 75%) identical to methyl 2,3-diaminobenzoate prepared above.

(f) Methyl 2-amino-3-N-benzoylaminobenzoate

A solution of ^benzoyl chloride (38.4 μΐ, 0.331 mmol) in tetrahydrofuran (5ml) was added dropwise to a solution of methyl 2,3-diaminobenzoate (50mg, 0.301 mmol) in dry tetrahydrofuran (5mlj, containing triethylamine (46 μΐ) and 4-dimethylaminopyridine (1.8mg, 5 mol %) .

After stirring the mixture for 24 hours at 45°C, solvents were evaporated, and the crude product was purified by column chromatography on silica gel, with petrol (40/60); ethyl acetate (3:2) as eluent. Recrystallisation from ethyl acetate-petrol (40/60), gave the title compound as white crystals. (60mg, 74%); (dg-DMSO, 200MHz) 3.95 (3H, s, 0CH3), 6.64 (2H, br s, Ar-NI^), 6.69-6.77 (1H, t, Ar-5H), 7.46-7.50 (1H, d, Ar-4H), 7.59-7.70 (3H, m, Ph-3 and Ph-3' 4H) , 7.81-7.85 (1H, d, Ar-6H) , 8.11-8,14 (2H, d, Ph-2H and Ph-2'H), 9.8-9.9 (1H, br, s, Ar-NHCO); m/z (El) 270 (M⁺), 253, 105.

(g) Methyl 2-amino-3-N-(4¹-methoxybenzovl)aminobenzoate

To a solution of methyl 2,3-diaminobenzoate (460mg,

2.77 mmol) in dry tetrahydrofuran (20ml) was added 4methoxybenzoyl chloride (378 μΐ, 2.77 mmol), triethylamine (385.5 μΐ, 2.77 mmol), and 4-dimethylaminopyridine (17mg, 5 mol%). The reaction mixture was stirred at room

AP/P/ 9 8/01183

AP S ϋ u 8 6 6 temperature overnight, yielding an insoluble precipitate that was collected by filtration. The filtrate was evaporated under reduced pressure and the residual solid was redissolved in boiling methanol, and hot filtered to remove the insoluble material. The solvent was removed in vacuo, and the solid residue was combined with the previously collected precipitate . Recrystallisation from aqueous methanol afforded white crystals of the title compound. (513.2mg, 62%); mp 179-180°C;

Found: C, 64.26; H, 5,31; N, 9.17.

Cl6^H16^N2°4 requires C, 64.0; H, 5.33; N, 9.33; ^vmax/cnv^_1 3425.54, 3341.54, 3277.84, 1699.24, 1632.12,

1251.11; δ_Η (dgDMSO, 200MHz) 3.92 (3H, s, OMe), 3.94 (3H, s, OMe), 6.59 (2H, s, Ar-NH₂), 6.68-6.75 (1H, t, Ar-5H),

7.13-7.17 (2H, d, J=8.8, Ph-3/3'H), 7.43,-7.46 (1H, d, Ar4H) , 7.79-7.83 (1H, d, Ar-6H), 8.07-8.12 (2H, d, J=8.8,

Ph-3.3'H), 9.7 (1H, br s, -NHCO-); 0_C (dgDMSO) 51.98,

55.76, 110.62, 113.79, 114.67, 125.0, 126.84, 129.12, 130.14, 133.20, 147.36, 162.21, 165.74, 168.33; m/z (El)

300 (M+), 135, 107, 77.

(h)_Methyl 2-phenvlbenzimidazole-4-carboxylate

AP/P/ 9 8/01183

A solution of methyl 2-amino-3-N25 benzoylaminobenzoate (6.3mg, 0.023 mmol) in glacial acetic acid (0.5ml) was stirred under reflux for 15 minutes. After cooling, the solvent was removed under reduced pressure to afford the title compound; (dgDMSO, 200 MHz) 4.09 (3H, s, OCH₃), 7.40-7.48 (1H, t, Ar30 5H) , 7.64-7.70 (3H, m, 2-Ph-3H and 3'-Ph-4H) , 7.93-7.97 (1H, d, Ar-4H), 8.06-8.10 (1H, d, Ar-6H), 8.39-8.41 (2H, d, 2-Ph-2/2'H), 12.4-12.5 (1H, br, s, Ar-NHCO).

AP Ο Ο Ο 8 6 6

EXAMPLE 2

Benzimidazole-4-carboxamide (Compound NU1066) (a) 1st Stage - Preparation of Benzimidazole-4carboxvlic acid (Compound NU1067)

A mixture of 2,3-diaminobenzoic acid (0.5g, 3.29 mmol) and formic acid (405 μΐ, 9.87 mmol) in hydrochloric acid (4M, 10ml) was heated under reflux for one hour.

The precipitate which formed on cooling was collected, redissolved in boiling methanol, and decolorised with activated charcoal. Evaporation of the solvent gave benzoxazole-4-carboxylic acid as a white powder (407.9mg,

77%)

Found: C, 46.11; H, 3.63; N, 13.27.

CgHgN2O2.HC1.0.5 H2O requires C, 46.28; H, 3.88; N, 13.49%;

S_H(dg-DMSO, 200 MHz) 7.7-7.8 '(1H, t, Ar-5H), 8.2-8.3 (2H, dd, Ar-4/6H), 9.65 (1H, s, imidazole-2H).

(b) 2nd Stage - Preparation of Benzimidazole-4carboxamide (Compound NU1066)

A suspension of benzimidazole-4-carboxylic acid (3.97.4 mg, 2.45 mmol) in thionyl chloride (10ml) was heated under reflux for 3.5 hours, and the thionyl chloride was removed by vacuum distillation. The residual solid was suspended in dry tetrahydrofuran (10ml) and added dropwise to concentrated aqueous ammonia (50ml) with stirring over 30 minutes. Excess solvent was removed in vacuo, and the residue was dissolved in a minimum volume of water and extracted with ethyl acetate (2 x 20ml) . The solid recovered on evaporation of the combined organic layers was dissolved in hydrochloric acid (0.1M, 10ml) and the insoluble precipitate was removed by filtration. The aqueous filtrate was carefully adjusted to pH 9 in increments of 1 pH unit, and ethyl acetate extractions (10ml) were undertaken at

AP/P/ 9 8/01183

AP C 0 Ο 8 6 6 each step. The combined extracts were dried (MgSO,/ and the solvent was evaporated. Recrystallisation from ethyl acetate furnished benzimidazole-4-carboxamide (50mg, 13%)

Found: C, 59.95; H, 3.90; N, 24.59.

C9H7N3O requires C, 59.63; H, 4.35; N, 26.09%; uv/nm 210, 270, 291; Vmax/cm’¹ 3321.84, 3150.16, 1747.73, 1680.21; δ_Η (dg-DMSO, 200 MHz) 7.4 (IH, t, Ar-5H) , 7.88.0 (3H, dd, Ar-4/6H) , 8.5 (IH, br s, imidazole-2H), 9.4 (IH, br s, CONH), 13.1 (IH, br s, CONH) ; m/z (El) 161 (M⁺), 141, 116, 99.

EXAMPLE 3

15* 2-Methylbenzimidazole-4-carboxamide (Compound NU1064) (a) 1st stage - Preparation of 2-Methylbenzimidazole-4carboxylic acid

Acetic acid (0.23ml) was added to a solution of 20 2,3-diaminobenzoic acid (200mg, 1.32 mmol) in hydrochloric acid (4M, 3.2ml) and the mixture was refluxed for 1 hour. Solvents were evaporated and the residual solid was redissolved in boiling methanol (5ml) and decolorised with activated charcoal. Removal of the solvent furnished 2-methylbenzimidazole-4-carboxylic acid as an amorphous white solid (167.5mg, 72%); δ_Η (dg-DMSO) 2.9 (3H, s, imidazole-2-CH₃), 7.6-7.8 (IH, t, Ar-5H) 8.1 (2H, d, Ar-4/6H) ; m/z (El 176 (M⁺) , 158,

130 (b) 2nd stage - Preparation of 2-Methylbenzimidazole-4carboxamide (Compound NU1064)

A suspension of 2-methylbenzimidazole-4-carboxylic

5 acid (5 00mg, 2.84 mmol) in thionyl chloride (10ml) was heated under reflux for 2 hours, and the thionyl chloride was removed by vacuum distillation. The solid residue was redissolved .in dry tetrahydrofuran, and added dropwise to concentrated aqueous ammonia solution (50ml)

AP/P/ 9 8/01 183

AP Ο Ο Ο 8 6 6 over 30 minutes, with stirring. The solvent was removed under vacuum, and the solid residue was redissolved in a minimum of hot water, filtered, and extracted with ethyl acetate (2 x 30ml) . Evaporation of the solvent afforded a brown solid which was recrystallised from ethyl acetate to give the title compound as a white solid (7O.img, 14%)

Found: C, 61.47; H, 4.96; N, 23.39.

C9H9N3O requires C, 61.71; H, 5.14; N, 24.0%;

uv/nm 209, 270; v-_max/cm^_1 3296.77, 3071.07, 1913.63,

1859.62, 1805.60; δ_Η (dg-DMSO, 200 MHz) 2.68 (3H, s, imidazole-2-CH3), 7.30-7.38 (1H, t, Ar-5H), 7.72--7.46 (1H, d, Ar-4H) , 7.86-7.90 (1H, d, Ar-6H), 7.72-7.90 (1H, br s, imidazole-ΝΉ), 9.4 (1H, br s, CONH), 12.8 (1H, brs,

CONH); m/z (EI) 175 (M+) , 158, 130.

EXAMPLE 4

2-Phenvlbenzimidazole-4-carboxamide (Compound NU1070) (a) 1st Stage - Preparation of 2-phenylbenzimidazole-4carboxvlic acid

A mixture of 2,3-diaminobenzoic acid (O.lg, 0.66 mmol), benzoic acid (80.2mg, 0.66 mmol) and polyphosphoric acid (-5ml) was heated at 150-160°C for 30 minutes, and, after cooling, crushed ice (~l0g) was added. Insoluble materials were removed from the dark solution by filtration, and the filtrate was extracted with ethyl acetate (2 x 20ml) to remove unreacted benzoic acid. The aqueous solution was cautiously neutralised with sodium hydroxide (10 M)., filtered, and the filtrate was extracted with ethyl acetate (2 x 30ml) . The combined extracts were dried (MgS0₄) and the solvent was evaporated. Chromatography on silica gel, with

5 dichloromethane:methanol (85:15) as eluent, gave the title compound (31.2mg, 20%); fijj (dg-DMSO, 200 MHz) 7.4 (1H, t, Ar-5H) , 7.62 (3H, br s, 3-Ph-4H and 3'-Ph-4H), 7.91 (1H, d, Ar-6H), 7.97 (1H, d, Ar-4H) , 8.39 (2H, d, Ph-2H and Ph2'-H); m/z (EI) 238 (M⁺), 220, 192, 77.

AP/P/ 9 8/01183 (b) 2nd Stage - Preparation of 2-phenylbenzimidazole-4carboxamide (NU107Q)

2-Phenylbenzimidazole-4-carboxylic acid (50mg, 0.21 mmol) was dissolved in dry tetrahydrofuran (10ml) thionyl chloride (16.8 gl, 0.231 mmol) and DMF (0.05ml) were added. The mixture was stirred at room temperature for 12 hours, when a white precipitate developed, and the suspension was added dropwise to stirred aqueous ammonia (10ml) over 10 minutes. The mixture was stirred for a further 30 minutes, diluted with water (20ml) , and neutralised with hydrochloric acid (4M). The white solid which was precipitated upon cooling, was collected by filtration to afford 2-phenylbenzimidazoIe-4-carboxamide (31mg, 62%); v_max/cm¹ 3320, 3180, 1660 and 1600; δ_Η (dg15 DMSO, 200 MHz) 7.45 (1H, t, Ar-5H), 7.72 (3H, d, 3-Ph4H) , 7.87 (1H, d, Ar-4H), 7.97 (1H, br s, CONH) , 7.99 (2H, d, Ar-6H), 8.38 (2H, d/ Ph-2-H and Ph-2-H), 9.5 (1H, br s, CONH); m/z (El) 237 (M⁺), 220, 192, 165, 77.

EXAMPLE 5

2-(4¹-Methoxyphenv)benzimidazole-4-carboxamide (NU1076) (a) 1st Stage - Preparation of Methyl 2-(4¹-methoxyphenyl) benzimidazole-4 -carboxylate Acetate Salt Methyl 2-amino-3-N- (4' -methoxybenzoyl)benzoate (480mg, 1.6 mmol) was dissolved in glacial acetic acid (15ml), and heated at 120°-130°C for 30 minutes. The solvent was removed and the solid residue was recrystalised from ethyl acetate-petrol (40/60) to yield the product as a white crystalline solid. (409mg, 75%),mp 141-142°C;

Found: C, 63.68; H, 4,79; N, 7.88;

C_1SH₁₄N₂O₃ · CH₃CO₂H requires C, 63.16,- H, 5.26; N, 8.19,Vmax/cm¹ 3375.33, 1718.46, 1696.80, 1282.81, 1257.81,

1257.34; δ_Η (dgDMSO), 200MHz) 2.02 (3H, s, CH₃CO₂H) , 3.97 (3H, s, OMe), 4.09 (3H, s, OMe), 7.21-7.25 (2H, d, J=8.6,

Ph-3/3'H), 7.39-7.46 (1H, t, Ar-5H), 7.90-7.93 (1H, d,

AP/P/ 9 8/01183

APO00866

Ar-4H), 8.00-8.04 (1H, d, Ar-6H), 8.36-8.40 (2H, d,

J=8.6, Ph-2/2'H), 12.1 (1H, s, Imz-H), 12.3-12.4 (1H, br, s, CH₃CO₂H); 0_C (dgDMSO) 21.35, 52.37, 55.64, 114.41,

121.68, 122.35, 124.34, 129.56, 153.63, 161.27, 166.13,

172.37; m/z (El) 282 (M+-CH₃CO₂H), 250, 222, 77, 60, 43,

32.

(b) 2nd Stage - Preparation of 2-(4¹-Methoxypheny) benzimidazole-4-carboxamide (NU1076)

The acetate salt of methyl (2- (4' -methoxyphenyl) benzimidazole-4 -carboxylate was dissolved in excess liquid ammonia and heated at 100°C in a sealed pressure vessel at 40 atmospheres overnight. The ammonia was allowed to evaporate, and the solid residue was collected and washed with ice cold waller (3 x 5ml) . Recrystallisation from aqueous methanol afforded the title compound (226.4mg, 80%); mp 26l-263°C;

Found: C, 66.07; H, 4.23; N, 15.29.

^C15^H13^N3°2· 0.2CH₃OH requires C, 66.70; H, 5.08; N,

15.35;

^vmax/^cm_1 3321.47, 3140.72, 1656.23, 1608.25, 1421.43,

1242.55; δ_Η (dgDMSO, 200MHz) 3.96 (3H, s, OMe), 7.23-7.27 (2H, d, J=8.6, Ph-3/3'H), 7.37-7.45 (1H, t, Ar-5H), 7.787.82 (1H, d, Ar-4H), 7.87 (1H, br s, Imz-H), 7.93-7.96 (1H, d, Ar-6H) , 8.27-8.31 (2H, d, .7=8.6, Ph-2/2'H), 9.49.5 (1H, br s, -CONH), 13.3-13.4 (1H, br s, -CONH); m/z (El) 267 (M⁺), 249, 222, 206, 77, 32.

EXAMPLE 6

- (4¹ -trifluoromethy1) benzimidazole-4-carboxamide (NU1077) (a) 1st Stage - Preparation of Methyl 2-amino-3-N-(4¹ 35 trifluoromethvlbenzoyl) aminobenzoate

To a solution of methyl 2,3-diaminobenzoate (300mg,

1.807 mmol) was added 4-trifluoromethylbenzoyl chloride (268.4 μΐ, 1.807 mmol), triethylamine (251.4 μΐ, 1.807 mmol) and 4-dimethylaminopyridine (llmg, 5mol%), and the

AP/P/ 9 8/01183

ΑΡΟ Ο Ο 8 6 6 mixture was stirred at room temperature overnight. The reaction solvent was removed under reduced pressure and the resulting solid was washed with ethyl acetate. Recrystallisation twice from methanol-water gave the title compound as a white solid. (83.6mg, 14%); mp 180181°C;

Found: C, 56.75; H, 3.50; N, 8.28.

^C16^H13^F3^N2°3 requires C, 56.80; H, 3.85; N, 8.28; uv/nm 222; δυ (dgDMSO, 200MHz) 3.93 (3H, s, OMe), 6.7010 6.76 (3H, m, Ar-5H, Ar-NH₂), 7.46-7.49 (1H, d, Ar-4H) ,

7.81-7.85 (1H, d, Ar-6H), 7.99-8.03 (2H, d) , 8.29-8.33 (2H, d) , 10.05 (1H, S, -NHCO-) ; ia/z (El) 338 (M⁺) , 321, 289, 145, 32.

(b) 2nd Stage z Preparation of Methyl 2-(4'-trifluoromethylphenyl)benzimidazole-4-carboxylate Acetate

Salt

Methyl 2-amino-3-N-(4'-trifluoromethylbenzoyl) aminobenzoate (75.7mg, 0.224 mmol) was dissolved in glacial acetic acid (5ml) and stirred at 125°C for 0.5 hour. The solvent was evaporated and the remaining white solid was washed with petrol .(40/60) to yield the title compound. (59.6mg, 70%); mp 138-140°C;

Found: C, 56.78; H, 3.98; N, 7.36;

C]_gH].2_F₃N₂O₂CH₃CO₂H requires C, 56.84; H, 3.94; N, 7.37. uv/nm 206, 319; δ_Η (dg-DMSO, 200MHz) 2.01 (3H, s,

CH₃CO₂H) , 7.44-7.52 (1H, t, Ar-5H), 7.97-8.14 (4H, m) ,

8.65-8.66 (2H, d) , 12.1 (br s, Imidazole-NH), 12.7-12.8 (1H, br s, CH₃CO₂H); itt/z (El) 320 )M⁺-CH₃CO₂H), 301, 288,

260, 145, 60, 43.

(c) 3rd Stage - Preparation of 2-(4¹-trifluoromethyl) benzimidazole-4-carboxamide (NU1077)

The acetate salt of methyl 2-(4'-trifluoro35 methylphenyl)benzimidazole-4-carboxylate was dissolved in excess liquid ammonia and heated at 100°C, in a sealed pressure vessel at 40 atmospheres, for 12 hours. The ammonia was allowed to evaporate, and the solid residue was washed with ice cold water (3 x 5ml).

AP/P/ 9 8/01183

APO Ο Ο 8 6 6

Recrystallisation from methanol-water yielded the product as fine white needles. (19.1mg, 48%); mp 301-305°C; Found: C,56.45; H, 3.50; N, 12.41.

Ci5HioF3N30.CH₃0^H requires C, 56.97; H, 4.18; N, 12.46;

δυ (dg-DMSO, 200MHz) 7.45 (1H, t, Ar-5H), 7.88-7.92 (1H, d, Ar-4H), 7.99 (1H, br s imidazole-ΝΉ), 8.03 (1H, d, Ar6H); 8.06-8.10 (2H, d, U=8.1), 8.55-8.59 (2H, d, J=8.1), 9.3-9.4 (1H, br s, -CONH), 13.7-13.8 (1H, br s, -CONH) ;

m/z (El) 288 (M+-NH₃) , 260, 69.

EXAMPLE 7

2- (4¹ -Hydroxyphenyl) -l-H-benzimidazole-4-carboxamide (Compound NU1085) ,

Under an argon atmosphere 1M boron tribromide in dichloromethane (3‘.8ml, 3.79 mmol) was transferred to a flask containing 2-(4'-methoxyphenyl)benzimidazole-420 carboxamide (NU 1076 from Example 5) (202.4mg, 0.758 mmol) . The resulting solution was refluxed for 24 hours using an air condenser. The solvent was removed by distillation to complete dryness. The solid residue was treated with 10% NaOH (10ml), followed by dropwise addition of concentrated hydrochloric acid to neutralise (pH 7) . The white precipitate was collected by filtration and dissolved in ethyl acetate (10ml). The organic solvent was washed with water (2 x 3ml) , dried over MgS0₄, and the product was obtained by removal of the solvent under reduced pressure. (109.5mg, 57%). mp 266-267°C;

Found C 63.27, H 4.37, N 15.67 C₁₄H_1;LN₃O2.0.75 MeOH requires C 63.04 H 4.69 N 15.76,- ^vitiaX'^cm^ 3424.01,

3384.16, 3309.20, 3249.55, 3155.62, 1642.35, 1618.02,

1594.50, 1577.74; δ_Η 7.03-7.07 (2H, d, J=8.5), 7.34-7.42 (1H, t) , 7.75-7.79 (1H, d) , 7.85 (1H, br s) , 7.90-7.94 (1H, d) , 8.15-8.19 (2H, d, J=8.5), 9.4-9.6 (1H, br s) ,

10.0-10.4 (1H, br s), 13.0-13.4 (1H, br s); m/z (El) 253 (M+), 236, 208, 93.

AP/P/ 9 8/01 183

ΑΡΟ Ο Ο 8 6 6

EXAMPLE 8

2- (4 ¹ -Methoxyphenyl) -l-methylbenzimidazole-4-carboxamide (Compound NU109Q)

2-(4'-Methoxyphenyl)benzimidazole-4-carboxamide (NU1076 from Example 5) (105.3mg, 0.394 mmol) and powdered potassium hydroxide (22mg, 0.394 mmol) were suspended in acetone (4ml) and stirred until all the solids had dissolved. Methyl iodide (24.6μ11, 0.394 mmol) was added and the reaction stirred at room temperature overnight. The solvent was removed ureter reduced pressure and the white solid residue purified by column chromatography with dichloromethane/methanol 95:5 to give fine white crystals ,of the title compound. (33.2mg, 30%) mp 289-292°C; Found C 68.62 H 5.36 N 14.67 Ο₁₆Η₁₅Ν₃Ο₂Requires C 68.33 Ή 5.34 N 14.95; voicin'¹) 3309.23, 3141.44, 1671.29, 1605.30, 1255.08, δ_Η3.95 (3H, s) , 4.02 (3H, s) , 7.22-7.27 (2H, d) , 7.44-7.52 (1H, t) , 7.86-8,00 (5H, m) , 9.4 (1H, br s, NH) ; m/z (El) 281 (M⁺) , 264,

250.

AP/P/ 9 8/01183

EXAMPLE 9

2-(4¹-Methoxyphenyl)-l-benzoylbenzimidazole-4-carboxamide (Compound NU1101)

A solution of 2-(4'-Methoxyphenyl)benzimidazole-4carboxamide (NU1076 from Example 5) (75.1mg, 0.281 mmol) and powdered potassium hydroxide (15.8mg, 0.281 mmol) was prepared in acetone (3ml) and stirred until all the solids had dissolved. Benzoyl chloride (32.6 μΐ, 0.281 mmol) was added and the solution stirred overnight at room temperature, with the production of a white precipitate. The solvents were removed under reduced pressure, and the white residue was purified by column chromatography using dichloromethane/methanol 95:5. The £8110/86 /d/dV

AP Ο Ο Ο 8 6 6 resulting solid was recrystallised from petrol 40/60 / ethyl acetate to give the pure product as brilliant white prisms. (15.6mg, 15%).

mp 207-210°C; Found C 70.45 H 4.60 N 10.99 ^{5 c}22^h17ⁿ3°3·⁰·^{25 CH}3^0H Requires C 70.45 H 4.47 N 11.08 v_max(cm-^{* 1 2 3}) 3445.99, 3318.55, 2922.99, 1689.79, 1666.36;

δ_Η 3.86 (3H, s, OCH₃), 7.02-7.06 (2H, d) , 7.50-7.65 (4H, m) , 7.72-7.82 (3H, m) , 7.88-7.92 (2H, d) , 8.08 (1H, s,

CONH) , 8.10-8.14 (1H, d) , 9.1-9.2 (1H, br s, CONH) ; m/z (El) 371 (M+), 105.

FURTHER EXAMPLES

The following further examples, and also some of 15 the examples already described, make use of certain common standard procedures. These comprise:

(1) Reaction of' Methyl 2,3-diaminobenzoate with Aryl Acid Chlorides (Standard Procedure A) (2) Benzimidazole Ring Formation by Acid Catalysed Cyclisation (Standard Procedure B) (3) Amide Formation by Reaction with Liquid Ammonia (Standard Procedure C)

The experimental details of these standard procedures are described below:

Standard Procedure A

An ice/salt bath cooled solution of methyl 2,3diaminobenzoate (1 equivalent), dry triethylamine (1-1.5 equivalents) and dimethylaminopyridine (DMAP - 5mol%) in half the required volume of dry tetrahydrofuran (THF) was prepared. The required acid chloride (1 equivalent) was dissolved in the remaining dry tetrahydrofuran (THF) and added to the cooled solution with stirring over 30

AP Ο Ο Ο 8 6 6 minutes. The reaction was allowed to warm slowly to room temperature and was stirred overnight. The solvent was filtered to remove a precipitate which was suspended in ethyl acetate, washed twice with water followed by saturated brine, and dried with MgSC>4. The organic layer was added to the reaction filtrate, and the solvent removed under reduced pressure. The solid residue was redissolved in ethyl acetate, washed twice with water followed by saturated brine, and dried with MgSC>4.

Removal of the solvents under reduced pressure left a solid residue which was purified by column chromatography and/or recrystallisation from suitable solvents.

Standard Procedure B

The starting material was dissolved in glacial acetic acid and plunged into a pre-heated oil bath at 120°C. The solution was heated for the appropriate time and then allowed to cool to room temperature. The acetic acid was removed under reduced pressure and the solid residue purified by column chromatography and/or recrystallisation from suitable solvents.

Standard Procedure C

The starting material was dissolved in a excess of freshly condensed liquid ammonia. This was heated to

SO °C within a sealed vessel, generating a pressure of 40 atmospheres, for 24 hours. The ammonia was evaporated, and the solid residue obtained purified by column chromatography and/or recrystallisation from suitable solvents .

AP/P/ 9 8/01183

AP Ο Ο Ο 8 6 6

EXAMPLE 10

2- (4¹ -Cyanophenyl) -l-H-benzimidazole-4-carboxamide (NU1092) (a)

1st Stage - Preparation of Methyl 2-amino-3-N-(4 diaminobenzoate μΐ, 1.81 mmol) cvanobenzoyl)aminobenzoate

Following standard procedure A, methyl 2,3(300mg, 1.81 mmol), triethylamine (251 and DMAP (llmg) were dissolved in THF (7.5ml) and cooled. To this was added 4-cyanobenzoyl chloride (299mg, 1.81 mmol) dissolved in THF (7.5ml).

The product was purified by column chromatography, dichloromethane/ methanol 99:1, recrystallisation from boiling methanol.

followed by (196mg, 37%) mp 198-202°C; Ymax(^cm_1^ 3486.40, 3374.02, 3245.61,

2231.25, 1688.04, 1646.65; δ_Η3.93 (3H, s, CO2CH3), 6.686.76 (1H, t) , 6.72 (2H, br - s, NH₂) , 7.45-7.49 (1H, d) , 7.81-7.86 (1H, d) , 8.11-8.15 (2H, d, J=8.4), 8.25-8.29 (2H, d, J=8.4), 10.01 (1H, br s, NH) ,· m/z (El) 295 (M⁺) ,

278, 263, 246, 130, 102.

(b) 2nd Stage - Preparation of Methyl 2-(4'~ cyanophenyl)-l-H-benzimidazole-4-carboxylate

Following standard procedure B, methyl 2-amino-3-N(4¹-cyanobenzoyl)aminobenzoate (301mg, 1.02 mmol) from

1st stage was heated in glacial acetic acid (10ml). The product was obtained by recrystallising twice using petrol 40/60 / ethyl acetate. (203mg, 72%) mp 195-198°C; v_max(cm^-1) 3447.66, 2228.84, 1691.90,

1288.11 δ_Η 4.09 (3H, s, CO₂CH₃), 7.44-7.53 (1H, t) , 7.978.01 (1H, d), 8.10-8.13 (2H, d, J=8.4), 8.58-8.62 (2H, d,

J=8.4), 12.8 (1H, br s); m/z (El) 277 (M⁺), 245, 217

AP/P/ 9 8/01183 (c) 3rd Stage - Preparation of 2- (4'-Cvanoohenvl) -1-#benzimidazole-4-carboxamide (NU1Q92)

Following standard procedure C, methyl 2-(4'cyanophenyl)-l-H-benzimidazole-4-carboxylate (169.5mg, 0.612 mmol) was treated with ammonia under pressure. The

APO Ο Ο 8 6 6 crude product was recrystallised from boiling methanol to yield the title compound pure as white crystals. (116.5mg, 73%) mp >310°C; Found C 67.81 H 3,89 N 20.87, C15H10N4O.0.2

MeOH Requires C 67.95 H 4.05 N 20.85; v^ay (cm^-3-) 3332.27,

3274.86, 3177.98, 2230.85, 1658.54, 1608.10; δ_Η 7.45-7.49

(1H,	t) ; 7.87-7.91	(1H,	d) ,	7.91 (1H,	br s) , 7	.98-8.02
(1H,	d) ; 8.13-8.17	(2H,	d,	J=8.3), 8	.50-8.54	(2H, d,
J=8.	3), 9.2-9.4 (1H	, br	s) ,	13.6-13.8	(1H, br	s) ; m/z
10 (El)	262 (M⁺), 245,	217,	102 .

EXAMPLE 11

2-(4¹-Nitrophenyl)-l-H-benzimidazole-4-carboxamide (NU1091) (a) 1st Stage - Preparation of Methyl 2-amino-3-N-(4¹nitrobenzoyl)aminobenzoate

Following standard procedure A, methyl 2,3diaminobenzoate (300mg, 1.807 mmol), dry triethylamine (276.6/xl, 1.988 mmol) and DMAP (llmg) were dissolved in dry THF (12ml). To this was added 4-nitrobenzoyl chloride (335.2mg, 1.807 mmol) in dry THF (12ml). Column chromatography with dischloromethane/methanol 99:1 followed by recrystallisation from methanol gave the product pure.

mp 196-197°C; Found C 57.08 H 3.78 N 13.25 C₁₅H₁₃N₃O₅Requires C 57.14 H 4.12 N 13.33; v^ay(cm^-1) 3382.31,

3293.01, 3256.56, 1702.05, 1657.83, 1525.37; δ_Η 3.94 (3H, s, CO₂CH₃), 6.70-6.78 (1H, t) , 6.66 (2H, br s, NH₂) ,

7.48-7.51 (1H, d) , 7.83-7.87 (1H, d) , 8.33-8.38 (2H, d,

J=8.8), 8.46-8.51 (2H, d, J=8.8), 10.15 (1H, br S, NH) ;

m/z (El) 315 (M⁺), 297, 265, 165.

(b) 2nd ;tage - Preparation of Methyl 2-(4'~

Nitrophenyl)-l-H-benzimidazole-4-carboxylate Following standard procedure B, methyl 2-amino-3-N(4'-nitrobenzoyl) aminobenzoate (340.2mg, 1.08 mmol) was

AP/P/ 9 8/01183

ΑΡ ϋ ϋ Ο 8 6 6 heated in glacial acetic acid (10ml) for 15 minutes. The product was obtained pure by recrystallisation from methanol. (208mg, 65%).

mp 208-210°C; Found C 60.69 H 3.57 N 13.96 C₁₅H₁₁N₃O₄5 Requires 60.61 H 3.70 N 14.14; ν_π3Υ(cm 3433.70,

1720	• 14,	1601.	84, 1513.07; δ_Η 4.21 (3H, s,	co₂ch₃),	7.57-
7.65	(1H,	t) ,	8.10-8.12 (1H, d) , 8.23-8.27	(1H, d),	8.60-
8.64	(2H,	d,	«7=8.8), 8.78-8.82 (2H, d,	«7=8.8) ,	13.04
(1H,	br s	, NH)	; m/z (El) 297 (M⁺), 265.

(c) 3rd Stage - Preparation of 2-(4¹-Nitrophenyl)-l-Hbenzimidazole-4-carboxamide (NU1091)

Following standard procedure C, methyl 2- (4·nitrophenyl)-l-H-benzimidazole-4-carboxylate was 15 dissolved in liquid ammonia and heated under ^constant ’volume in a pressure vessel. The product was purified by column chromatography f rom ’ dichloromethane/methanol 99:1 and recrystallised· from methanol.

mp >310°C; δ_Η 7.48-7.56 (1Η, t), 7.90-7.94 (1H, d), 8.00 (1H, s, NH) , 8.00-8.04 (1H, d) , 8.52-8.56 (2H, d, «7=8.8),

8.60-8.64 (2H, d, «7=8.8), 9.3-9.4 (1H, br s, NH) , 13:814.0 (1H, br S, NH)

EXAMPLE 12 25

2-(3¹-Trifluoromethylphenyl)-l-H-benzimidazole-4carboxamide (NU1093) (a) 1st Stage - Preparation of Methyl 2-amino-3-N-(3¹ 3 0 trifluoromethylbenzoyl) aminobenzoate

Following standard procedure A, methyl 2,3diaminobenzoate (200mg, 1.205 mmol), dry triethylamine (704μ1, 5.06 mmol) and dimethylaminopyridine (DMAP,

7.3mg) were dissolved in dry THF (7.5ml) . To this was added 3-trifluoromethylbenzoyl chloride (183 μΐ, 1.205 mmol) in dry THF (7.5ml) . Column chromatography with dichloromethane/methanol 99:1 removed impurities and the more polar product was eluted with dichloromethane /methanol 97:3. Recrystallisation from methanol gave

AP/P/ 9 8/01183

AP 0 0 0 8 6 6 the product as a white solid. (160.4mg, 26%).

mp 157-159°C; Found C 57.14 H 3.57 N 8.10 C₁₆H₁₃F₃N₂O₃

Requires C 56.80 H 3.85 N 8.28,- v_max (cm^-1) 3368.48, 3283.82, 2953.87, 1705.98, 1650.77, 1250.02; δ_Η3.93 (3H,

S, CO₂CH₃), 6.69-6.77 (IH, t) , 6.73 (2H, s, NH₂) , 7.457.49 (IH, d) , 7.82-7.92 (2H, m) , 8.06-8.10 (IH, d) , 8.408.44 (IH, d) , 8.48 (IH, Ξ, 2 ¹-H) , 10.1 (IH, s, NH) ; m/z (El) 338 (M⁺) , 320, 288, 260, 173, 145.

(b) 2nd Stage - Preparation of Methyl 2-(3¹-trifluoromethylphenyl )-l-ff-benzimidazole-4-carboxylate acetate salt

Following standard procedure B, a glacial acetic acid (6ml) solution of methyl 2-amino-3-N-(3¹-trifluoro15 methylbenzoyl)aminobenzoate was heated for 15 minutes». Removal of the solvent under reduced pressure followed by drying at high vacuum yielded the product as a pure white solid. (154.2mg, 96%).

mp 105-107°C; Found C 56.93 H 3.78 N 7.32 ²⁰ C₁sH₁₁F₃N₂O₂.CH₃CO₂H Requires C 56.84 H 3.95 N 7.37 VmaxCcm-¹) 3438.30, 3339.14, 2959.13, 1707.99, 1328/24,

1313.53; δ_Η 2.01 (3H, S, CH₃CO₂H) , 4.09 (3H, S, CO₂CH₃),

7.44-7.51 (IH, t), 7.79-8.13 (4H, m), 8.71-8.75 (IH, d),

8.82 (IH, s), 11.8-12.2 (IH, br s), 12.8-13.0 (IH, br s) ;

m/z (El) 320 (M+-CH₃CO₂H), 288, 260.

(c) 3rd Stage - Preparation of 2-(3¹-trifluoromethyl phenyl)-1-H-benzimidazole-4-carboxamide (Compound NU1093)

Following standard procedure C, the acetate salt of methyl 2-(3'-trifluoromethylphenyl) -l-H-benzimidazole-4carboxylate (134.8mg, 0.358 mmol) was treated with excess liquid ammonia in a sealed vessel. The product was purified by recrystallisation from methanol, to yield off-white needles. (78mg, 72%).

mp 268-270°C; Found C 57.68 H 3.82 N 12.96 C₁₅H₁₀F₃N₃0.0.6CH₃OH Requires C 57.74 H 3.82 N 12.95; ^vmax(^cm_1) 3488.83, 3348.86, 3176.45, 1667.66, 1600.93,

1329.63,- δ_Η 7.44-7,.52 (IH, t), 7.88-8.04 (5H, m) , 8.66AP/P/ 9 8/01 183

ΑΡύ ϋ ΰ 8 6 6

8.70 (1Η, d) , 8.70 (1Η, Ξ, 2' Η), 9.3 (1Η, br s, NH) , 13.6 (1Η, br s, NH); m/z (El) 305 (M⁺) , 288, 260, 145.

EXAMPLE 13 5

2- (3 ¹ -Methoxy-phenyl) -l-H-benzimidazole-4-carboxanu.de (NU 1098) (a) 1st Stage - Preparation of Methyl 2-amino-3-N-(3¹ 10 methoxybenzoyl)aminobenzoate

Following standard procedure A, a solution of methyl 2,3-diaminobenzoate (670.3mg, 4.038 mmol), dry triethylamine (842.6 μΐ, 6.057 mmol) and DMAP (25mg) in dry THF (20ml) was prepared. A solution of 315 methoxybenzoyl chloride (567 μΐ, 6.038 mmol) in dry THF (20ml) was added to this. The resulting solid residue * was purified by column chromatography using dichloromethane/methanol 99:1 and the product was obtained pure after two recrystallisations from petrol

40/60 / ethyl acetate. (282.6mg, 23%) mp 124-125°C; Found C 63.90 H 5.11 N 9.24 C₁₆H₁₆N₂O₄

Requires	C 64.0 H 5.33 N 9.33; (cm’¹)	3386	.19,
3292.38,	1697.97, 1586.87, 1520.79, 1250.27; δ_Η 3	.92	(3H,
S), 3.93	(3H, s) , 6.61 (2H, s, NH₂) , 6.68-6.76	(1H,	t) ,
25 7.22-7.27	(1H, d), 7.44-7.47 (1H, d), 7.49-7.57	(1H,	t) ,
7.66 (1H,	S, 2 ¹-H) , 7367-7.71 (1H, d) , 7.79-7.84	(1H,	d) ,

AP/P/ 9 8/01183

9.8 (1H, s, NH) ; m/z (El) 300 (M+), 283, 135, 107.

(b) 2nd Stage - Preparation of Methyl 2-(3'-methoxy30 phenyl)-l-H-benzimidazole-4-carboxylate Acetate

Salt

Following standard procedure B, methyl 2-amino-3-N(3'-methoxybenzoyl)aminobenzoate (356.9mg, 1.19 mmol) was warmed in glacial acetic acid (12ml. The removal of the solvent under reduced pressure followed by recrystallisation with petrol 40/60 I ethyl acetate afforded the title compound pure. (235.6mg, 58%) mp 93-94°C; Found C 62.66 H 5.13 N 8.06 ^C16^H14^N2°3-^CH3^CO2^H Requires C 63.16 H 5.26 N 8.18

APO ο Ο 8 6 6 ^vmax^^cm_1) 3453.23, 3375.10, 1706.75, 1257.40; δ_Η 1.99 (3Η, s, CH₃CO₂H), 3.96 (3Η, s), 4.06 (3Η, s) , 7.15-7.21 (1Η, d) , 7.38-7.46 (1H, t) , 7.51-7.59 (1H, t), 7.91-8.00 (3H, m) , 8.04-8.08 (1H, d) , 12.0 (1H, s) , 12.5 (1H, s) ;

m/z (El) 282 (M⁺-CH₃CO₂H) , 250.

(c) 3rd Stage - Preparation of 2-(3¹-Methoxyphenyl)-1H-benzimidazole-4-carboxamide (NU1098)

Following standard procedure C, a liquid ammonia solution of methyl 2-(3'-methoxyphenyl)-l-Hbenzimidazole-4-carboxylate (203mg, 0.596 mmol) was heated under constant volume. The solid residue was recrystallised from methanol to give the pure product (73.5mg, 46%).

mp 223-225°C; Found C 67.52 H 4.91 N 15.62 C₁₅H₁₃N₃O₂Requires C 67.42 H 4.87 N 15.73; Vmaxfcm^-1·) 3408.59, 3383.94, 3168.65, 1662.05, 1625.86, 1603.39; δ_Η 3.99 (3H, s, OCH₃), 7.22-7.27 (1H, d), 7.43-7.51 (1H, t), 7.58-7.66 (1H, t), 7.85-8.01 (5H, m) , 9.4-9.5 (1H, br s) , 13.5 (1H, br s) ; m/z (El) 267 (M⁺) , 250.

EXAMPLE 14

AP/P/ 9 8/01 183

2-(2¹-trifluoromethylphenyl)-l-H-benzimidazole-425 carboxamide (NU1104) diaminobenzoate solution with (a) 1st Stage - Preparation of Methyl 2-amino-3-N-(2'trifluoromethylbenzoyl) aminobenzoate Following standard procedure A, methyl 2,3(564mg, 3.4 mmol) in a THF (20ml) triethylamine (709μ1, 5.1 mmol) and dimethylaminopyridine (21mg) was stirred and to this was added a THF (2 0ml) solution of 2-trifluoromethylbenzoyl chloride. The resulting oily residue was absorbed onto silica and then subjected to column chromatography with dichloromethane/methanol 99:1 as eluant. The product was obtained pure after recrystallisation from petrol 40/60 / ethyl acetate. (303mg, 26%) .

mp 163-166°C; Found C 56.91 H 3.75 N 8.29 C₁₆H₁₃F₃N₂O₃

AP Ο Ο Ο 8 6 6

Requires C 56.80 Η 3.35 Ν 8.23; 3329.85,

3243.90, 2955.52, 1696.66, 1663.58, 1312.69; δ_Η 3.94 (3Η, s, CO₂CH₃), 6.58 (2Η, S, ΝΗ₂) , 6.74-6.82 (1Η, t) ,

7.57-7.62 (1Η, d) , 7.79-8.03 (5Κ, τη) , 10.0 (1Η, s, ΝΗ) ;

m/z (ΕΙ) 338 (Μ⁺) , 321, 289, 173, 145.

(b) 2nd and 3rd Stages - Preparation of 2-(2'~ trifluoromethyl)-l-H-benzimidazole-4-carboxamide (NU1104)

Upon subjedting the product of the 1st stages successively to standard procedures B and C, the title compound was obtained.

¹⁵ EXAMPLE 15 *

- (4¹ -Aminoohenyl) -1-H-benz imidazole-4 - carboxamide (NU1103) (a) 1st Stage - Preparation of Methyl-2-amino-3-N-(4¹aminobenzoyl)aminobenzoate ao

Methyl-2-amino-3-N-(4¹-nitrobenzoyl)aminobenzoate (from 1st stage of Example 11) was suspended in methanol (40ml) and a slurry of 10% palladium catalyst on activated carbon (~50mg) in methanol (10ml) was added to o

oo cn £

£ <

The solution was 2 hours. After

TM) to remove the removal of the this with stirring under argon, atmospherically hydrogenated for filtration through CELITE (Regd.

catalyst the product was obtained by solvent under reduced pressure to give a white solid which was dried under high vacuum. (204.lmg, 92%). mp 197-200°C; Found C 62.95 H 5.30 N 14.39 C₁₅H₁₅N₃O₃

Requires	C 63
3374.96,	3348 .)
s, co₂ch₃	), 5.
3.73 (2H,	d) , ι
7.82 (2H,	d) ,
235, 207,	120 ,

9.4 (1H,

H 5.26 N 14.73;

v, max (cnT¹) 3472.55, (1H, t), 7.42-7.47 (1H, d), 7.78S, NH) ; m/z (El) 285 (M⁺), 267,

APO Ο Ο 8 6 6 (b) 2nd Stage - Preparation of Methyl 2-(4'aminophenyl)-l-H-benzimidazole-4-carboxylate

Acetate Salt

Following standard procedure B, the treatment of methyl 2-amino-3-N-(4aminobenzoyl) aminobenzoate (186.5mg, 0.654 mmol) with hot glacial acetic acid (8ml) for 30 minutes yielded the title compound following recrystallisation from petrol 40/60 / ethyl acetate.

(113.4mg, 91%) mp 162-164°C; Found C 62.60 H 5.04 N 12.73 C₁₅H₁₃N₃O₂.CH₃CO₂H·Requires C 62.39 H 5.20 N 12.84; Vmaxfcm-¹) 3450.66, 3369.25, 3254.20, 1692.41, 1607.56,

1253.80; δ_Η 2.02 (3H, s, CH₃CO₂H) , 4.OS (3H, s, CO₂CH₃),

5.81 (2H, s, NH₂), 6.75-6.80 (2H, d, J=8.6), 7.32-7.40 (IH, t) , 7.83-7.86 (IH, d) ,, 7.93-7.97 (IH, d) , 8.08-8.13 (2H, d, J=8.6), 11.9 (IH, s), 12.1 (IH, br s) ; Itt/z (El) 267 (M⁺-CH₃CO₂H), 235, 207, 92, 60.

(c) 3rd Stage - Preparation of 2-(4¹-Aminophenyl)-l-ffbenzimidazole-4 - carboxamide (NU1103)

Following standard procedure C, the acetate salt of methyl 2-(4'-aminophenyl)-l-H-benzimidazole-4-carboxylate (113mg, 0.346 mmol) was treated with liquid ammonia under pressure for 24 hours. The pure title compound was isolated with column chromatography of the crude material using dichloromethane/methanol 90:10 (21.4mg, 25%) mp 237-240°C; δ_Η 5.90 (2H, s, NH₂) , 6.79-6.83 (2H, d, *7=8.3), 7.31-7.39 (IH, t), 7.71-7.75 (IH, d) , 7.84 (IH, s, NH), 7.88-7.92 (IH, d), 8.00-8.04 (2H, d, *7=8.3), 9.59.6 (IH, br s, NH), 13.0 (IH, br s, NH).

AP/P/ 9 8/01183

ΑΡΟ ϋ Ο 8 6 6

ASSAY FOR PARP INHIBITORY ACTIVITY

Compounds of the present invention, particularly those detailed in the preceding Examples, have been tested in vitro for activity as PARP inhibitors using the following methods and materials.

In principle, the PARP assay used relies upon activating endogenous PARP (as hereinafter described) in cells containing exogenous [³²P]-NAD⁺ introduced therein by suspending the cells in a solution of [³²P]-NAD⁺ to which they have been rendered permeable in an initial pre-treatment step. The poly(ADP-ribose) which is then synthesised by the enzyme can be precipitated by tri15 chloracetic acid (TCA) and the amount of radio-labelled ³²P incorporated therein measured,’ e.g. using a scintillation counter, to give a measure of the activity of the PARP under the particular conditions of the experiment. By repeating the experiment following the

0 same procedure, and under the same conditions, in the presence of each compound to be tested the reduction, in enzyme activity, representative of the inhibitory effect of the test compound, can then be ascertained from the reduction, if any, of the amount of [³²P] measured in the

TCA precipitated poly(ADP-ribose).

The results of this assay may be expressed in terms of percentage inhibition or reduction in activity for one or more different concentrations of each compound tested, or it may be expressed in terms of that concentration of the tested compound which reduces the enzyme activity by 50%, i.e. the IC50 value. Thus, with a range of different compounds a set of comparative values for inhibitory activity can be obtained.

In practice, L1210 murine leukaemia cells have been used as a source of the PARP enzyme after being rendered permeable to exogenous [³²P]NAD by exposure to hypotonic buffer and cold shock. In the preferred technique which

AP/P/ 9 8/01183

AP Ο ΰ Ο 8 6 6 has been found to give exact and reproducible results, a defined amount of a small synthetic oligonucleotide, in particular a single strand oligonucleotide having the palindromic sequence CGGAATTCCG, is introduced into the cell suspension for activating the PARP enzyme. This oligonucleotide sequence snaps back on itself to form a double-stranded molecule with a single blunt end and provides an effective substrate for activation of PARP. Its behaviour as a potent activator of the enzyme was confirmed in the tests carried out.

The experimental protocol adopted, in which a synthetic oligonucleotide as mentioned above is introduced as a specific activator of PARP, discriminates between PARP and_# other mono-ADP-ribosyltransferases in the cells. Thus, introduction of such synthetic oligonucleotides causes a 5 to 6 fold stimulation in the radioactive label 'incorporated and this is attributable solely to PARP activity.

Further details of the assay are given below.

Materials

AP/P/ 9 8/01 183

The materials used included the following:

DTT (Dithiothreitol)

A lOOmM (15.4mg/ml) solution (for use as an antioxidant) was made up, divided into 500μ1 aliquots and stored at -20°C. Hypotonic buffer·.

9mM Hepes 4.5% Dextran 4.5mM MgCl₂ (214mg/100ml) (4.5g/100ml) (92mg/100ml)

The above ingredients were dissolved in about 80ml distilled water, pH was adjusted to 7.8 (NaOH/HCl) , the solution was then made up to 100ml with distilled water, and stored in a refrigerator.

DTT was added to

Isotonic buffer:

APO 0 0 8 6 6

5mM just before use (50/il/ml) .

40mM Hepes 13 0mM KC1 4% Dextran 2mM EGTA 2.3mM MgCl₂225mM Sucrose (1.9g/200ml) (1.94g/200ml) (8g/200ml) (152mg/200ml) (94mg/200ml) (15.39g/200ml)

The above ingredients were dissolved in about 150ml distilled water, pH was adjusted to 7.8 (NaOH/HCl), the solution was then made up to 200ml with distilled water and stored in a refrigerator. DTT was added to 2.5mM just before use (25gl/ml).

NAD

NAD was stored as a solid in pre-weighed aliquots at -20 °C. ' From these, solutions of a concentration of approximately 6mM (4-4.5mg/ml) were freshly made up shortly before performing an assay, and the molarity was checked by measuring the optical density (O.D.) at 260nm. The stock solution was then diluted with water to give a concentration of 600μΜ and a small amount of ³²P labelled NAD was added (e.g. 2-5/xl/ml) .

Oligonucleotide

The oligonucleotide having the palindromic sequence CGGAATTCCG, synthesised by conventional means, was vacuum dried and stored as pellets in a freezer. Before use, it was made up to 200gg/ml in lOmM Tris/HCl, pH 7.8, with each pellet being dissolved completely in 50ml of buffer. The solution was then heated to 60°C in a water bath for 15 minutes, and allowed to cool slowly to ensure correct reannealing. After adding 9.5ml of buffer, the concentration was checked by measuring the optical density of a diluted sample at 260nm.

AP/P/ 9 8/01183

AP Ο Ο Ο 8 6 6

The main solution was then diluted to a concentration of 200/ig/ml and stored in 500μ1 aliquots in a freezer, ready for use.

TCA

Solutions of TCA (Trichloroacetic acid) were prepared at two concentrations. 10% TCA + 10% sodium pyrophosphate, and 1% TCA + 1% sodium pyrophosphate.

Cells

The L1210 cells used as the source of the

PARP enzyme were maintained as a suspension culture in RPMI medium + 10% foetal bovine serum + <* glutamine and antibiotics (penicillin and streptomycin) . HEPES and sodium bicarbonate were also added, and the cells were seeded in 100ml2 00ml of medium such that there would be a concentration of approximately 8 x 10⁵/ml at the time of carrying out an assay.

Method

The compounds being tested were generally made up as a concentrated solution in DMSO (Dimethyl sulphoxide).

The solubility of the compound was then checked by adding a quantity of the DMSO solution to a quantity of the isotonic buffer, in the required final proportions that were to be used in carrying out the assay, and after an interval the solution was examined under a microscope for any signs of crystals forming.

A desired quantity of the cells, ascertained by counting with a haemocytometer, was then centrifuged (1500rpm in a Europa model 24M centrifuge for 5 minutes), the supernatant removed, and the pellets obtained were resuspended in 20ml Ca⁺⁺ Mg⁺⁺ free phosphate buffered saline (Dulbeco's modification A, abbreviated Dul A)· at 4°C before centrifuging again at 1500rpm and 4 °C. After again removing the supernatant,

AP/P/ 9 8/01183

APO Ο Ο 8 6 6 the cells were resuspended at a ccncentraticn of 3 x 10⁷cells/ml in ice cold hypotonic buffer and left for 30 minutes on ice. Nine volumes were then added of ice cold isotonic buffer, and the cells, now rendered permeable to exogenous NAD⁺, were then used within the next hour for carrying out an assay. The permeablisation of the cells may be checked at this stage by adding duplicate aliquots of cells to an equal volume of trypan blue, leaving for 5 minutes and then counting on a haemocytometer. Those rendered permeable will take up the Trypan blue and appear coloured.

The assay was then carried out using for convenience plastic 15ml conical bottomed assay tubes set up in a shaking water bath at 26°C which is the optimum temperature for this enzyme. In a typical assay using the oligonucleotide solution at a concentration of 5gg/ml and the test compound/DMSO solution at a concentration of 2%, and carrying out the assay in quadruplicate, there would then be placed in each assay tube 5μ1 of the oligonucleotide solution, 50gl of the 600μτη NAD + [32_p] _ NAD solution, 8/xl of the test compound/DMSO solution, and 37μ1 of water. Prior to the start of the experiment this cocktail would be pre-warmed for 7 minutes at 26°C, as would be also the cell suspension. The reaction would then be started by adding 300μ1 of the cell suspension. The reaction would be stopped by adding 2ml of the icecold 10% TCA + 10% sodium pyrophosphate solution.

In addition to the above, six assay tubes would usually be set up as blanks, these containing the same ingredients as above but, before adding the cell suspension, TCA solution is added to prevent any reaction from taking place. This enables corrections to be applied for any non-specific binding of the labelled material to the filter used (see below) .

After adding the cell suspension at timed intervals to each of the assay tubes, the 10% TCA + 10% sodium

AP/P/ 9 8/01183

APO Ο Ο 8 6 6 pyrophosphate at 4°C was added to each assay tube exactly 5 minutes after addition of the cell suspension to that tube. Then, after leaving the tubes on ice for a minimum time of one hour, the contents of each individual tube were filtered through an individual filter funnel of a suction filter apparatus using GF/C filter elements (rough side up) wetted with 10% TCA. After filtering the contents of each tube and rinsing the filters several times with 1% TCA + 1% sodium pyrophosphate solution, the filters were carefully removed and dried before being placed in individual scintillation vials. Four additional scintillation vials were also set up as reference standards containing 10μ1 of the βΟΟμΜ NAD + [32p]-NAD solution, 10ml scintillant then being added to each vial. Counting was carried out for 2 minutes on a β counter to obtain measures of the present, and thus the amount of the poly(ADP-ribose) and activity of the PARP enzyme .

RESULTS OF IN VITRO PARP INHIBITION STUDIES

Apart from applying the PARP enzyme assay in accordance with the standard procedure outlined above to a range of compounds which have been made in accordance with the present invention, for comparison purposes it was also applied to certain benzamide compounds, in particular benzamide, 3-hydroxybenzamide and 3methoxybenzamide, that are already known to exhibit certain PARP inhibitory activity. A tabulated list of

0 some exemplary compounds which have been made and/or studied is hereinafter presented in the TABLE at the end of the present description, together with the PARP inhibition assay results obtained in one or more different experiments, expressed either as the percentage inhibition at a 10μΜ concentration or, more usually, as IC5Q values, for the compounds when tested using the assay hereinabove described.

In reviewing this list, the known PARP inhibitors

AP/P/ 9 8/01183

APO Ο Ο 8 6 6 benzamide, 3-amincbenzamide and 3 -methoxybenzamide, may be regarded as reference compounds. Although the results varied somewhat, in general the compounds of the present invention which were tested showed a relatively high degree of inhibitory activity. Of especial interest were the benzimidazole carboxamides having the reference numbers NU1064, NU1066, NU1086 and, most particularly, NU1070, NU1076, NU1077, NU1085, NU1090, NU1091, NU1092, NU1093 and NU1098, of which NU1091 and NU1092 showed exceptionally high inhibitory activities.

FURTHER BIOLOGICAL ACTIVITY STUDIES

Again using cultures of the murine leukaemia L1210 cell line, growth inhibition experiments were carried out to assess the cytostatic effects of the compounds and clonogenic survival assays' were performed to assess cytotoxicity, especially in relation to use of the compounds in conjunction with DNA damaging cytotoxic agents such as cytotoxic antitumour drugs or gamma irradiation. DNA damage and the effect of the PARP inhibitors on the process of DNA strand break formation and repair has also been assessed by carrying out DNA strand break assays and monitoring by alkaline elution in accordance with published techniques.

In the growth inhibition assays, typically the L1210 cells would be seeded at 1 x 10⁴/ml in triplicate in 24 well multidishes, and 24 hours later the compounds or drugs being tested would be added in selected combinations and concentrations. At this time one set of replicates would be counted using a Coulter counter (Nq), and 48 hours later the remaining samples would be counted (N₂) . The percentage (%) growth inhibition of drugtreated samples could then be estimated. In drug combination experiments, where evidence of synergistic effects on cell growth or clonogenicity was being sought, a single, fixed concentration of a cytotoxic drug sample,

AP/P/ 9 8/01183

AP Ο Ο Ο 8 6 6

e.g. temozolomide (ΤΜ) , would be taken as the control value .

Examples of in vitro Cytotoxicity Assays

In a particular example of an in vitro cytotoxicity assay using the compound NU1064 (2-methylbenzimidazole-4carboxamide), L1210 murine leukaemia cells were incubated with increasing concentrations of NTJ1064 in the presence or absence of ΙΟΟμΜ of the methylating agent, temozolomide, in a final DMSO concentration of 1% DMSO, for 24 hours at 36°C. The cells were pelleted, resuspended in fresh medium, counted and seeded for colony formation in 0.15% agarose in drug-free medium.

15_r After 1 week colonies of viable cells were stained with MTT (1ml 0.5mg/ml) and counted. The plating efficiency of the control (89%) and temozolomide alone (32%) were normalised to 100% relative survival and the plating efficiency of the NU1064-treated cells expressed as a percentage of these values.

There was a modest reduction in cell survival caused by NU1064 alone (relative plating efficiency at 100μΜ and 200μΜ NU1064 = 72% and 54%, respectively) but a very marked increase in temozolomide cytotoxicity with increasing concentrations of NU1064 (relative plating efficiency at 100 and 200μΜ NU1064 = 28% and 2%, respectively) indicating a NU1064-concentration-related potentiation of temozolomide cytotoxicity. An illustration of these results is presented by FIG. 1 of the accompanying drawing.

• In other, clonogenic survival, assays, typically the L1210 cells would be exposed to varying concentrations of TM ± a fixed concentration of PARP inhibitor for a fixed time of 16 hours, prior to counting and seeding for colony formation in 0.12-0.15% agarose in drug-free medium. After 7-10 days colonies would be stained with 0.5mg/ml MTT and counted by eye on a gridded

AP/P/ 9 8/01183

ΑΡΟ 0 0 8 6 6 light box. This then enables survival curves to be plotted and DEF₁₀ values to be obtained, DEF^g being defined as the ratio of the concentration of TM that reduces survival to 10% divided by the concentration of

TM that reduces survival to 10% in the presence of a fixed concentration of PARP inhibitor.

In further clonogenic survival assays gamma ray irradiation may be used to damage the cells. Typically,

L1210 cells (3ml, 4 x 10³/ml in plastic bijoux bottles) would be irradiated at 4°C with varying doses of gamma rays in the presence or absence of the compound being tested and a final concentration of 2% DMSO. The cells would then be incubated at 37 °C for 2 hours in the continued presence or absence of PARP inhibitor prior to seeding for colony formation. *

Repair of potentially lethal damage (PLD) occurs when cells are held in stationary-phase following initiation of PLD prior to allowing cell division to take place. In further typical experiments to test potential PARP inhibitors, L1210 cells have been allowed to repair gamma ray PLD in the presence or absence of the test compound as follows: L1210 cells were maintained in culture until they had attained stationary phase (>10⁶cells/ml) . They were diluted to 1.5 x 10⁵/ml in conditioned medium from stationary-phase cultures to prevent further cell division. Replicate 2ml samples of cells in plastic bijoux were held on ice prior to and immediately following 8 Gray gamma ray irradiation. 1ml of 3x final concentration of the test compounds made up in conditioned medium from stationary cultures would then be added to give appropriate final concentrations (e.g. 10⁶cells/ml in 1% DMSO + test compounds) , and the cells would be incubated at 37°C for 0, 2 or 4 hours prior to resuspending in drug-free medium and seeding for colony formation. Unirradiated stationary phase cultures incubated at 37°C for 0, 2 or 4 hours with 1% DMSO + the same amount of test compound provide appropriate controls

AP/P/ 9 8/01 183

ΑΡΟ Ο Ο 8 6 6 for determining relative cell survival. In the absence of PARP inhibitor cell survival would normally increase with time allowed for PLD repair to take place. For example, in one set of experiments, when seeded immediately after irradiation (no repair) only about 0.2% of the cells survived, but after a 4 hour repair period this had increased to 0.7%. An effective PARP inhibitor blocks this repair, thus reducing the survival rate.

With regard to the DNA strand break assays previously mentioned, typically samples of L1210 cells would be incubated’for a certain time, e.g. l hour, with a fixed concentration, e.g. 150μΜ, of temozolomide and, apart from a control, in the presence of increasing concentrations of the PARP inhibitors tested. The more effective the· inhibitor, the greater the rate of the alkaline elution (a measure of extent of strand breakage) compared to temozolomide alone.

In general, the studies carried out fully support the belief that the PARP inhibitory characteristics -of the compounds tested reflect an ability of these compounds to potentiate the cytotoxicity of DNA damaging agents, such as certain cytotoxic antitumour drugs and radiation used in radiotherapy. Accordingly, having regard to their' strong PARP inhibitory characteristics, the compounds of this invention can be expected to be especially useful for administration in conjunction with such cytotoxic drugs or radiotherapy in order to potentiate the cytotoxic effect of the latter in the course of medical treatment as hereinbefore indicated.

Summary

Although the present invention should be regarded overall as comprising each and every novel feature or combination of features disclosed herein, the main aspects of the invention comprise, principally but not

AP/P/ 9 8/01 1.8 3

APO Ο Ο 8 6 6 exclusively, broadly the following:(i) Novel compounds of formula (I) as defined herein;

(ii) Compounds of formula (I) with substituents as hereinbefore defined (including pro-drug forms and salts thereof) for therapy or for use in medicine and in the manufacture of medical preparations, useful for example as PARP inhibitors to be administered in conjunction with cytotoxic drugs or with radiotherapy to potentiate the effectiveness of the latter in treatment of cancer;

(iii) Processes for the preparation of novel compounds of formula (I) as defined herein, including any novel intermediate compounds produced iji carrying out such processes,· (iv) Pharmaceutical formulations comprising a compound of formula (I) as defined herein together with a pharmaceutically acceptable carrier therein; and (v) Processes for the preparation of a pharmaceutical formulation as defined in (iv) above, e.g. by methods referred to herein.

AP/P/ 9 8/01183

AP O Ο Ο 8 66

House No.	Name	Structure	% Inhibition at 10 μΜ or IC₅₀ vaiue
Ref	benzamide	0 II
	C₇HtO MW= 121.1	cr	IC_i0= 12.4 ±3.1 μΜ
Ref	3-hydroxybenzamide	0
	C₇H₇NO₂ MW =137	OH	ICj₀ = 8.0 ± 3.5 μΜ (7)
Ref	3-methoxybenzamide	0
	C₈H₉NO₂ MW= 151	och₃	55
NU1O64	2-methylbenzimidazole-4- -carboxamide	0	1C_5O= 1.09 ±0.23 μΜ (3)
	C₉H₉N₃O MW = 175.38	\ ^N HN-{ ch₃	-
NU1066	benzim idazole-4-carboxamide	0	1C_5O= 1.26μΜ
	C₈H₇N₃O MW = 161.16	\ ^N HN-^!J	IC_J0= 1.02μΜ
NU1067	benzim idazole-4carboxyiic acid	O ιΤ®	Inactive
	C₈H₆N₂O₂ 162.14	r~ HN—
NUI070	2-phenylbenzimidazole-4- carboxamide	O	IC₃₀ = 92 nM
	C_UH,,N₃O 237.26	r ^H<	IC₅„ = 103 nM
		o

ΑΡ/Ρ/ 9 8/01183

APO Ο Ο 8 6 6

NU1076	2-{4-methoxyphenyl) benzimidazole-4- carboxamide 26728	0	ICjq = 59 nM
0 HN—	'n h och₃
NU1077	2-(4-trifluoro-		0 II
	methylphenyl) benzimidazole-4-	Π	<^NHj	IC_J0 ’ 75 nM
	carboxamide	V
	^C15^H10^N3^OF3	HN-	V
	305.25		Q
			Cf=₃
NU1O85	2-(4-hydroxvphenyl) benzim idazole-4-	0	-CONHj f	IC_J0 = 77 nM
	carboxamide	Ύ	N
		HN	4
	1N3O2		X
	253 26		M
			OH
NU1086	2-trifluoromethyl- benzimidazole-4-		.CONH2	ΙΟ₃₀-1.6μΜ
	carboxamide	L .	Γ
		V	Ή
	^Ι6Ηΐ₃Ν₃ύ₃	HN-^
	28121		cf₃
NU1090	2-(4-mexhoxyphenyi)-iV-		CONHj	IC_io--lOOnM
methylbenzimidazole-4- carboxamide	Q

	^CI6^HI5^N3°2 23121	Me-^N	b
			0CH3
NU1091	2-(4-nitropnenyi)-		,conh₂	IC₅₀ = 22 nM
benzim idazo le—t-	f \|
	carboxamide	V	k
	C\|₄H,₀N₄O₃	HN-	k
	232.25		M
			no₂

ΑΡ/Ρ/ 9θ/01 183

Ah000866

NU1092	2-(4-cyanophenyl)benzim idazo ie-4carboxamide C₁₄H₁₀N₄O 26227	QC HN-/ V/ CN	IC_JO = 33 nM
NU1093	2-(3-tri fluoro methy i- pheay l)benzimidazo le-4carboxamide C₁₅H₁₀N₃OF₃		IC_J0 = 76 nM
	30525	VjK
NU1098	2-<3-methoxyphenyi) benzim idazo le-4carboxamide c_l5H₁₃N₃o₂ 26728	0 pi ^NHl HN—/ O^·	IC₃₀ = 130 nM
NU1101	A'-benzoyl-2-(4methoxyphenyl)benzim idazo le-4carboxamide	0	IC_J0 = 027 μΜ
	C₂₂H₁₇N₃O₃	• t>
	37129
NUU03	2-(4- aminophenyl}benzim idazo le-4carboxamide C \|₄H₁₂N₄O	gS \ M	IC_J0 =· 91 nM
	25227	v? \ NHi
NU1104	2-(2-trifluoromethyl- phenyl)benzimidazole-4- carboxamide C\|jH₁₀NjOF₃ 30525	G. o	Not tested

ΑΡ/Ρ/ 9 8/01183

NUI105

,ν-carboxybenzy 1-2-(4medioxyphenvl)benzimidazole-4carboxamide

C13H19N3O4

Claims

1. Use of a compound as herein defined for the manufacture of a medical or veterinary preparation for

5 use in therapy for inhibiting activity of the enzyme poly(ADP-ribose)polymerase or PARP (also known as ADPribosyl transferase or ADPRT),' such enzyme inhibition constituting an element of a therapeutic treatment, said compound providing the active PARP enzyme inhibiting

10 agent and being a benzimidazole-4-carboxamide having the general structural formula I or a pharmaceutically acceptable salt and/or pro-drug form thereof, characterised in that in structural formula I 25

R is selected from hydrogen, alkyl, hydroxyalkyl (e.g. CH₂CH₂OH) , acyl (e.g. acetyl or benzoyl) or an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group,

30 and

R' is selected from hydrogen, alkyl, hydroxyalkyl (e.g. CH₂CH₂OH) , acyl (e.g. acetyl or benzoyl) or an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group.

2 . Use of a compound as claimed in Claim 1 wherein the or each alkyl group present, either as such or as a moiety in an alkoxy or other group, contains 1-6 carbon

AP/P/ 9 8/01 183 atoms .

APO00866

3. Use of a compound as claimed in Claim 1 or 2 wherein

R represents an optionally substituted phenyl group having the structural formula II wherein R_1; R₂ and Rg are each selected independently from H, hydroxy, alkoxy, NO₂, N₃, NRgRg (Rg and Rg each being independently hydrogen, alkyl or alkoxy), NHCOR₃ (R₃ being alkyl or aryl), CO₂R₄ (R₄ being H or alkyl), an amide (e.g. CONH₂), tetrazole, alkyl, hydroxyalkyl, CW₃ or W (W being halogen), and CN.

AP/P/ 9 8/01 183

4. Use of a compound as claimed in Claim 3 wherein R]_

25 is a group other than hydrogen and is in the 4'-position, and wherein R₂ and Rg are each hydrogen.

5. Use of a compound as claimed in any of the preceding claims wherein

30 R' represents an optionally substituted phenyl group having the structural formula III

AP 000866 wherein R7, Rg and R^o are each selected independently from H, hydroxy, alkoxy, NO2, N₃, NRgRg (R5 and Rg each being independently hydrogen, alkyl or

5 alkoxy), NHCOR3 (R3 being alkyl or aryl) , CO₂R₄ (R4 being H or alkyl) , an amide (e.g. CONH2) , tetrazole, alkyl, hydroxyalkyl, CW3 or W (W being halogen), and CN.

6. Use of a compound as claimed in Claim 5 wherein R

7 is a group other than hydrogen and is in the 4'-position, and wherein Rg and R^g are each hydrogen.

15 7. Use of a compound as claimed in Claim 1 wherein R is selected from methyl, ethyl, n-propyl, i-propyl, n<· butyl, t-butyl and cyclohexyl.

8. Use of a compound as claimed in Claim 1 wherein R' 20 is hydrogen or alkyl and R is phenyl or benzyl having at least one substituent in the benzene ring which is selected from hydroxy, alkoxy, NO₂, N3, NRgRg (Rg and Rg each being independently hydrogen, alkyl or alkoxy),

NHCOR3 (R₃ being alkyl or aryl) , CO2R4. (R4 being H or 25 alkyl), an amide (e.g. CONH₂), tetrazole, alkyl, hydroxyalkyl, CW3 or W (W being halogen) , and CN.

AP/P/ 9 8/01 183

9. Use of a compound as claimed in Claim 1 which compound is one of the following:

(a) 2-methylbenzimidazole-4-carboxamide;

(b) benzimidazole-4-carboxamide;

(c) 2 -phenylbenzimidazole-4-carboxamide ,(d) 2-(4'-methoxyphenyl)benzimidazole-4-carbcxamide;

(e) 2-(4'-trifluoromethylphenyl)benzimidazole-4carboxamide ,· (f) 2-(4'-hydroxyphenyl)benzimidazole-4-carboxamide,· (g) 2-trifluoromethylbenzimidazole-4- carboxamide ,(h) 2- (4 ' -methoxyphenyl) -N-methylbenzimidazole-4carboxamide;

AP000866 (i) 2- (4 ' -nitrophenyl) benzimidazole-4-carboxamide;

(j ) 2- (4 ' -cyanopheny 1) benzimidazole-4-carboxamide;

(k) 2- (3 ' -trifluoromethylphenyl) benzimidazole-4carboxamide;

(l) 2- (3 ' -methoxyphenyl)benzimidazole-4-carboxamide;

(m) 2- (4 ' -methoxyphenyl) -l-N-benzoylbenzimidazole-4carboxamide, (n) 2- (4' -aminophenyl)benzimidazole-4-carboxamide (o) 2- (2 ' -trifluoromethylphenyl) benzimidazole-4 carboxamide, (p) 2V-carboxybenzyl-2- (4 ' -methoxyphenyl) benzimidazole-4-carboxamide.

10. Use of a compound as claimed in any of the

15 preceding claims wherein the compound is in the form of a pro-drug having a substituent group selected from ♦

phosphate, carbamate and amino acid.

11. Use of a compound as claimed in Claim 10 wherein

20 the pro-drug form is a phosphate derivative of a compound having the general structural formula I.

12. Use of a compound as claimed in Claim 11, said compound being in the form of a phosphate pro-drug

25 provided by a water-soluble ammonium or alkali metal phosphate salt derived from a compound of structural formula I that has at least one hydroxyl group substituent.

AP/P/ 9 8/01183

3 0

13. Use of a compound as claimed in Claim 12 wherein the compound of structural formula I from which the phosphate pro-drug is derived has a hydroxyl group substituent that is reacted with a dibenzvl phosphonate.

35

14. For use in therapy as an active pharmaceutical substance, a benzimidazole compound having the general structural formula I

APO Ο Ο 8 6 6

10 or a pharmaceutically acceptable salt and/or pro-drug form thereof, characterised in that in structural formula I

15 R is selected from hydrogen, alkyl, hydroxyalkyl (e.g. CH₂CH₂OH), acetyl, benzoyl and an optionally* substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group, subject to the proviso that R is not 4'-methanesulphonyloxy-2'20 methoxyphenyl or 4'-methanesulphonylamino-2'methoxyphenyl and does not represent a phenyl group having a substituent which is an alkylsulphenyl, alky 1sulphinyl, a1kanesu1ph0ny1 or alkylsulphoximino group, an alkyl-sulphoximino

25 group substituted at the nitrogen atom by an alkanoyl, alkylsulphonyl or hydroxycarbonylalkylenecarbonyl group, an ethoxy or n-propoxy group each of which is substituted in the terminal position by an alkylsulphenyl, alkylsulphinyl,

30 alkanesulphonyl or alkylsulphoximino group, an alkoxy-carbonylamino or an N-alkylaminocarbonylamino group;

and

R' is selected from hydrogen, alkyl, hydroxyalkyl

35 (e.g. CH₂CH₂OH), acyl (e.g. acetyl or benzoyl) and an optionally substituted aryl (e.g. phenyl) group, subject to the proviso that R' does not include a biphenyl or substituted biphenyl group;

for use as an active pharmaceutical substance.

AP/P/ 98/01183

APO Ο Ο 8 6 6

15. A compound having the general structural formula I or a pharmaceutically acceptable salt thereof, wherein

15 R is selected from hydrogen, hydroxyalkyl (e.g.

CH₂CH₂OH), acetyl, benzoyl and a substituted aryl « (e.g. a substituted phenyl) group, subject to the proviso that R is not 4'-methanesulphonyloxy-2'methoxy-phenyl or 4¹-methanesulphonylamino-2'20 methoxy-phenyl and does not represent a phenyl group having a substituent which is an alkylsulphenyl, alkylsulphinyl, alkanesulphonyl or alkylsulphoximino group, an alkyl-sulphoximino group substituted at the nitrogen atom by an

25 alkanoyl, alkylsulphonyl or hydroxycarbonylalkylenecarbonyl group, an ethoxy or n-propoxy group each of which is substituted in the terminal position by an alkylsulphenyl, alkylsulphinyl, alkanesulphonyl or alkylsulphoximino group, an

30 alkoxy-carbonylamino or an N-alkylaminocarbonylamino group; and

R' is selected from hydrogen, alkyl, hydroxyalkyl (e.g. (ΖΗ2<3Η₂ΟΗ) , acyl (e.g. acetyl or benzoyl) and

35 an optionally substituted aryl (e.g. phenyl) group, subject to the proviso that R' does not include a biphenyl or substituted biphenyl group.

AP/P/ 9 8/01183 ^s0 Ο ο 8 6 6

18. A compound as claimed in Claim 17 wherein R^ is a group other than hydrogen and is in the 4'-position, and wherein R₂ and Rg are each hydrogen.

19. A compound as claimed in any of Claims 14 to 18 wherein

R' represents an optionally substituted 10 phenyl group having the structural formula

III wherein R₇, Rg and R^q are each selected independently from H, hydroxy, alkoxy, NO2, N3, NR5R5 (Rg and Rg each being independently hydrogen, alkyl or

25 alkoxy), NHCOR3 (R3 being alkyl or aryl) , CO2R4 (R4 being H or alkyl) , an amide (e.g. CONH₂), tetrazole, alkyl, hydroxyalkyl, CW3 or W (W being halogen), and CN.

20. A compound as claimed in Claim 19 wherein R₇ is a group other than hydrogen and is in the 4'-position, and wherein Rg and R]_q are each hydrogen.

35

21. A compound as claimed in Claim 14 or 15 wherein R is selected from methyl, ethyl, n-propyl, i-propyl, nbutyl, t-butyl and cyclohexyl.

22. A compound as claimed in Claim 14 or 15 wherein R'

AP/P/ 9 8/01183

ΑΡΟ Ο Ο 8 6 6 is hydrogen and R is either a phenyl or a benzyl group having at least one substituent in the benzene ring which is selected from hydroxy, alkoxy, NO₂ , N₃ , NR₅R₆ (R₅ and Rg each being independently hydrogen, alkyl or alkoxy),

5 NHCOR₃ (R₃ being alkyl or aryl) ,· CO₂R₄ (R₄ being H or alkyl), an amide (e.g. CONH₂), tetrazole, alkyl, hydroxyalkyl, CW₃ or W (W being halogen), and CN.

23. A compound as claimed in Claim 14 or 15 which is

10 one of the following:

(a) 2-methylbenzimidazole-4-carboxamide;

(b) benzimidazole-4-carboxamide;

(c) 2- (4'-methoxyphenyl) benzimidazole-4-carboxamide;

(d) 2-(4'-trifluoromethylphenyl)benzimidazole-415 carboxamide; _t (e) 2- (4 ¹-hydroxyphenyl) benzimidazole-4 - carboxamide ,· (f) 2 -trifluoromethylbenzimidazole-4-carboxamide;

(g) 2-(4'-methoxyphenyl)-N-methylbenzimidazole-4carboxamide ,·

20 (h) 2-(4'-nitrophenyl)benzimidazole-4-carboxamide;

(i) 2-(4' -cyanopheny 1) benzimidazole-4-carboxamide,(j) 2-(3¹-trifluoromethylphenyl)benzimidazole-4carboxamide;

(k) 2-(3'-methoxyphenyl)benzimidazole-4-carboxamide,·

25 (1) 2-(4'-methoxyphenyl)-l-N-benzoylbenzimidazole-4carboxamide, (m) 2-(4'-aminophenyl)benzimidazole-4-carboxamide (n) 2-(2'-trifluoromethylphenyl)benzimidazole-4carboxamide,

3 0 (o) N-carboxybenzyl-2 - (4'-methoxyphenyl) benzimidazole-4-carboxamide.

24. A compound as claimed in any of Claims 14 to 23 wherein the compound is suitable for oral or intravenous

35 therapeutic administration and is in the form of a prodrug having a substituent group selected from phosphate, carbamate and amino acid.

25 .

AP/P/ 9 8/01183

A compound as claimed in Claim 24 wherein the proAP Ο Ο Ο 8 6 6

23. A compound as claimed in Claim 14 or 15 which is one of the following:

(a) benzimidazole-4-carboxamide ,(b) 2- (4' -methoxyphenyl) benzimidazole-4-carboxamide,(c) 2-(4'-trifluoromethylphenyl)benzimidazole-4 carboxamide;

(d) 2-(4¹-hydroxyphenyl) benzimidazole-4-carboxamide,(e) 2 - trif luoromethylbenzimidazole-4 - carboxamide,(f) 2-(4¹-methoxyphenyl)-N- methylbenzimidazole-4 carboxamide,· (g) 2-(4¹-nitrophenyl) benzimidazole-4-carboxamide ,· (h) 2-(4’-cyanophenyl)benzimidazole-4-carboxamide,· (i) 2-(3’-trifluoromethylphenyl) benzimidazole-4 carboxamide,· (j) 2-(3’-methoxyphenyl)benzimidazole-4-carboxamide;:

(k) 2- (4' -methoxyphenyl) -l-N*-benzoylbenzimidazole-4carboxamide, (l) 2-(4'-aminophenyl)benzimidazole-4-carboxamide (m) 2-(2'-trifluoromethylphenyl)benzimidazole-4 carboxamide, (η) N-carboxybenzyl-2-(4'-methoxyphenyl)benz imidazole-4-carboxamide .

24. A compound as claimed in any one of Claims 14 to 23 25 wherein the compound is suitable for oral or intravenous therapeutic administration and is in the form of a prodrug having a substituent group selected from phosphate, carbamate and amino acid.

ΑΡ/Γ7 9 8/01183

30 25. A compound as claimed in Claim 24 wherein the prodrug form is a phosphate derivative of a compound having the general structural formula I.

26. A compound as claimed in Claim 25, said compound

3 5 being in the form of a phosphate pro-drug provided by a water-soluble ammonium or alkali metal phosphate salt derived from a compound of structural formula I that has at least one hydroxyl group substituent.

ΑΡΟ Ο Ο 8 6 6

27. A compound as claimed in Claim 2 6 wherein the compound of structural formula I from which the phosphate pro-drug is derived has a hydroxyl group substituent that is reacted with a dibenzyl phosphonate.

28. A process for preparing a compound as claimed in Claim 17 comprising the steps of reacting an alkyl 2,3diaminobenzoate with an aryl acid chloride, treating the product with acetic acid at an elevated temperature to

10 bring about benzimidazole ring formation, and reacting with liquid ammonia to form the amide derivative.

29. A compound as claimed in any one of Claims 14 to 27 for use in therapy as an active PARP-inhibiting

15 substance.

30. Use of a compound as claimed in any one of Claims 14 to 27 for the manufacture of a medical or veterinary preparation for use in therapeutic treatment of a mammal.

31. A pharmaceutical formulation or composition containing a compound as claimed in Claim 29 made up in unit dosage form together with a pharmaceutically acceptable carrier for administration to a mammal likely

25 to benefit from treatment with a PARP-inhibiting agent in the course of therapy.

K>

CO co u

GL <

32. A pharmaceutical formulation or composition for medical use comprising an effective PARP-inhibiting

30 amount of a compound as claimed in any one of Claims 14 to 27 together with a pharmaceutically acceptable carrier.

33. A pharmaceutical formulation or composition as 35 claimed in Claim 31 or 32 for use in conjunction with cytotoxic agents or radiotherapy in antitumour treatment.

34. A pharmaceutical composition containing an effective PARP inhibiting amount of a compound as claimed in Claim 29 in admixture with a therapeutically useful